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 Recombinant DNA technology and the ability to produce recombinant proteins 
have significantly changed the world of pharmaceutical market. Recombinant DNA 
technology using E. coli cells has successfully produced many therapeutic proteins. In 
this study, the designed tag Ark-RUBY-tag facilitates rapid, and reproducible purification 
of recombinant proteins expressed as inclusion bodies in E. coli cells. Purification of 
Ark-RUBY-fused recombinant protein(s) can be obtained by using imidazole fractions. 
Target protein can be easily removed from the Ark-RUBY-tag by enzymatic cleavage. 
Ark-RUBY-fused recombinant proteins can be quantitatively detected using polyclonal 
antibodies. Ark-RUBY-tag can be used to purify small peptides. By using Ark-RUBY-
tag, purified recombinant protein regains fully biologically active form. Therefore, 
bioactive protein has wide range of application in drug-delivery.  
Copper is crucial in many cellular functions. It is known that copper is necessary 
in non-classical secretion by inducing multiprotein realize complex, but the involvement 
of copper in complex formation is not clear. In this study, the role of copper in non-
classical protein secretion of IL-1α was investigated. This framework demonstrates the 
role of copper to induce IL-1α dimerization under in vitro conditions. The dimerization 
mechanism is mediated by the single cysteine at position 143 that gets oxidized resulting 
in the formation of an inter-disulfide bond. The ratio of copper to induce IL-1α 
dimerization is one to two that means one copper can induce two molecules of IL1-α. The 
binding affinity of IL-1α to copper study showed that IL-1α binds to copper with Kd 
value 1.9 μM, which suggests IL-1α is copper binding protein. Also, some binding 
affinity experiments were conducted to elucidate whether copper is the only metal that 
induce dimerization. Some metals showed good binding affinity, but no one induced 
dimerization. Interestingly, corpus form showed high binding affinity, but it did not 
induce dimerization. Also, the monomer and the dimer forms of IL-1α have binding 
affinity to S100A13 with Kd values 1.30 μM and 1.34 μM respectively, which could be 
crucial in the non-classical secretion of signal-less IL-1α.  
The study also shows that Amlexanox (AMX), the anti-allergic drug, can bind to 
IL-1α and chelates copper with kd 1.9 μM and 1.6 μM respectively. It also inhibits the 
copper induced dimer formation of IL-1α. The mechanism that underlies dimer formation 
inhibition of AMX is either because it binds close to cysteine 143 of IL-1α where copper 
can bind and inhibits the induction of homodimer formation of IL-1α by masking the 
thiol group of Cys134 or by chelating copper and preventing it from binding to IL-1α. 
The results of AMX role in inhibiting dimer formation of IL-1α may help in designing a 
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Classical and non-classical protein secretion 
Signal peptide mediates protein secretion  
Cellular growth, progress, and communication need large number of different 
proteins that are synthesized in the ribosomes and transported to endoplasmic reticulum 
(ER)-Golgi apparatus1. In order to response to exogenous stimuli, newly synthesized 
proteins are exported by secretory system to their final destinations2. The secretory 
pathway applies specialized processes to the newly made proteins such as post-
translational modifications, protein sorting, and secretion. During protein synthesis, 
protein translocation into ER membrane is an initial and critical step in protein 
biosynthesis in eukaryotes3-5. ER contains chaperons that provide good environments for 
nascent proteins by facilitating proteins folding and correct proteins conformation. Also, 
ER works as proteins folding checkpoint that eliminates unfolded proteins before 
delivering to Golgi machine6, 7. Protein trafficking has been an area of discussion for a 
long time since Blobel and colleagues pioneered the basis of proteins translocation across 
intracellular membranes8.Reaching the right targets, newly made proteins need to be 
carried to protein sorting in the ER-Golgi system. In biological system of eukaryotic 
cells, signal peptide mediates proteins translocation across the membrane like system of 
ER that composes the secretory machine of living cells. Passing the ER existing sites, 
proteins are packed into membranous vesicles. After vesicles carrying proteins are 
delivered to Golgi apparatus, post Golgi apparatus cargos undergo fusion with the plasma 
membrane that results in the release of conventional secretory proteins into extracellular 
chamber. Each delivered protein requires a valid cellular address tag to govern protein 
export from the synthesis site to functional sites9. However, many aspects of protein 
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transporting processes were not clear. Synthesized proteins contain specific amino acid 
sequences that is called signal segment guiding the protein to the final destination9, 10. 
Intracellular compartments are delivered right proteins based on the signal segment. 
Signal segments are either a linear sequence of amino acids or a given residues forming 
up for interaction in the correct three-dimensional conformation of the cargo protein10. 
Each organelle is received a specific protein based on the interaction between the 
different receptors on their surface with a specific signal sequence, thus the information 
that are encoded in the signal sequence directs the specificity of targeting (Figure 1). 
Once a protein/receptor interaction has occurred, some kinds of translocation channels 
are opened. In mammalian cells, specific channels are called translocons that translocate 
newly synthesized proteins into final destination11, 12. Sometimes, for some proteins, it 
needs to reach a sub compartment within the target organelle4, 13. Lastly, once the 
translocation across the membrane is complete, a specific protease removes the signal 
sequence from the mature protein14, 15.  
Signal-less proteins and Non-classical pathways  
In classical protein secretion, proteins containing N-terminal signal peptide 
translocate into the lumen of ER, which is followed by ER/Golgi dependent transport to 
the cell surface for example, albumin, fibrinogen, and immunoglobulin8. However, signal 
peptide is not presented in many primary structure of different proteins and yet they exert 
their actions by binding to specific surface receptor16, 17. Moreover, signal-less peptide 
secreted proteins play a key role in many physiological processes such as inflammation, 
angiogenesis, and cell growth and differentiation18. Some secretory proteins are known 
for extracellular functions, but they do not have signal peptides and ER does not mediate 
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their membrane transportation into extracellular space19.These proteins are found to be 
involved in diseases. Examples of these proteins are interleukin-1 α, interleukin-1β, 
galectin 1 and 3, β galactoside specific lectins, fibroblast growth factor 1 and 2, infection 
related cell surface markers of Leishmania parasites (HASP family), and viral proteins 
such as Herpes simplex tegument proteins vp22 and HIV-TAT proteins etc. Interestingly, 
these proteins have non-endoplasmic localization or Golgi apparatus localization, with no 
ER/Golgi post translation modification such as glycosylation and most importantly their 
release cannot be interfered by protein secretion inhibitors such as berfeldin A, which is 
the classical proteins secretion inhibitor20. These findings bring a new term in proteins 
secretory mechanism that assures fully cellular functions in absence of signal peptides. 
Therefore, proteins secretion that mediates out of ER/Golgi system is called non-
classical/unconventional protein secretion process21, 22. Unconventional secretory 
pathway involves four mechanisms (Figure 1), two of which include intracellular vesicles 
of endocytic system such as secretory lysosomes and exosomes and the third export 
mediates plasma membrane-resident transport and the last one involves the plasma 
membrane shedding of micro-vesicles23, 24. FGF2 export is mediated through the cell 
membrane. Pores formation helps in moving leaderless proteins through without breaking 
the membrane. During stress, membrane pores construction needs fully folded leaderless 
proteins that accumulate near and interact with phosphatidylinositol 4,5-bisphosphate 
(P1P2) of cytoplasmic side of the membrane. The interactions induce conformational 
changes of P1P2 that triggers pores formation. Once the pores are made, leaderless 
proteins can easily translocate to the extracellular space. Even though pores formation 
explains how the membrane is kept intact, it does not elucidate how proteins that do not 
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interact with P1P2 can induce oligomerization to make pores. FGF1 and FGF2 are 
prototypic members of FGFs family and they share some structural properties, but FGF1 
secretion requires another signal-less protein to form multiprotein complex that includes 
S10A13, sphingosine kinase, synaptotagmin, and annexin 2. Then, with the help of 
annexin 2, the membrane is flipped outside to release the protein complex. Some 
cytoplasmic proteins are secreted during inflammation by either cell lysis or changing in 
cell membrane permeabilization. Cell lysis occurs during the inflammation while some 
immune cells work to destroy irritant action. Best example for lysis protein secretion is 
IL-1 β. However, some researchers have shown that IL-1 β is secreted without destroying 
the cells. It is secreted when cells permeability changes after gasdermin-N, a result of 
caspase 1 catalyzed gasdermin cleavage, is inserted in the cell membrane. However, IL-1 
α secretion needs to interact with S100A13 to be exported outside the cells.  
Non-classical protein secretion of IL-1α 
The most common form of IL-1α found in cells is the precursor protein25, 26. 
Precursor IL-1α (proIL-1α) can generate the IL-1R1 signaling once it is released. ProIL-
1α is processed by the Ca2+ dependent protease calpain to form mature form of IL-1α 27, 
25,26. IL-1α export requires Cu2+ and its binding protein S100A13. IL-1α-S100A13 
complex is in a Cu2+ dependent manner and the complex formation is released from the 
cells when the cells are exposed to heat stress16, 28. Interestingly, precursor IL-1α is active 
by its own and the necessity of cleavage is not clear. The latest study suggested that 
cleavage process might increase its potency29. Several proteases play role in precursor IL-
1α cleavage include, neutrophil elastase, NK-granzyme-B, mast cell chymase, and 
calpain proteolysis30.  
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Figure 1: Demonstrates different mechanisms of proteins transport (export) systems.  
 
It is well known that products of cleavage of enzymatic proteolysis are more 
potent than the precursor protein in activating cells. During NK-mediated killing of target 
cells, granzyme-B cleavage of proIL-1α occurs. ProIL-1α can be cleaved to enhanced 
inflammatory response of inflammatory cells. Cleavage of the precursor takes away the 
carboxyl-terminal mature part of the molecule where the NLS which is the nuclear 
translocation and DNA binding part of the protein31. Therefore, the mature form of IL-1α 
produces from cleavage process, cannot be retained in the nucleus leading to its release 
from the cell with great affinity to the receptor. Caspase-1 was recognized to have a role 
in processing and secretion of IL-1β. It is secreted in combination with IL-1β from 
specialized secretory lysosomes. In regard to IL-1α, Caspase-1 might assist the secretion 
of IL-1α32. Several studies on Caspase-1 knockout mice shown a reduction in the 
secretion of both IL-1 α and IL-1β33-80. At intracellular level, a binding protein, called 
interleukin-1 receptor 2 (IL-1R2), protects IL-1α precursor. Certainly, IL-1R2 binding to 
precursor IL-1α inhibits its cleavage and release from necrotic cells. It is suggested that 
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caspase-1 helps removing IL-1R2 from precursor IL-1α that ultimately leads to cleavage 
and secretion of IL-1α. Several players are affecting the inflammatory potential 
including, the levels of IL-1 α, calpain, the extent of necrosis and the expression of 
intracellular IL-1R2, and its cleavage by caspase-1 and intracellular levels of Ca2+26, 34, 35.  
Copper and Unconventional protein secretion mechanism 
In non-classical protein secretion of FGF1, copper is required in order to form 
multi proteins complex of FGF1, P40, S100A13 and Syt1. Kumar group has 
demonstrated that copper stimulates FGF1 dimers as well as S100A13 dimers in the 
stressed release of FGF136. Many proteins have been linked to FGF1 secretion during 
stress. Sphingosine kinase 1 (SK1), a copper-binding protein, mediates sphingosine-1-
phosphate formation, lacks the signal peptide sequence, and is also secreted by non-
classical protein secretion. In presence of copper, FGF1 is found to make high molecular 
weight complex with SK137. Prudovsky group has showed that SK1 has high affinity to 
copper that makes the protein to be copper donor in stress release of FGF1. Treating the 
cells with copper chelating agent called tetrathiomolybdate (TM) blocks the effects of 
copper induce dimerization leading to decrease cancer growth. However, large expression 
of SK1 seemed to rescue FGF1 release in present of TM. Many studies have shown that 
proteins binding to different metals have various effects38. For example, S100A13 binds 
to calcium as well as copper, but each ion has diverse binding matters. It is very 
interesting that the bindings sites of those two ions are located close to each other on the 
S100A13. Moreover, thermodynamic stability of S100A13 dimers totally depends on 
these ions in a way that this protein structure usually destabilized significantly when it 
binds to copper whereas binding to calcium structure is more stabilized. Copper not only 
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stimulates protein conformational changes but also it helps in cellular communications. 
Even though IL-1α, IL-1β, FGF1, and FGF2 have low amino acids homology, they share 
unique biological aspects. They all have no signal peptide, secreted by unconventional 
protein secretion, and they all compose twelve β-sheets. More interesting, some of them 
share the secretion pathway. For example, IL-1α and FGF1 export is similar in 
responding to cellular stress39. In addition, some complex structure formation upon stress 
exposure follows similar traits in both proteins. This is noted in the release complex 
formation that includes S100A13 and Cu2+-dependence, which is stress-dependent40. As 
SK1 is a copper provider for stress secretion of FGF1, it may work for IL-1α (Figure 2). 
Figure 2: Elucidates the proposed mechanism of copper induces IL-1 α secretion by non-
classical secretin16. 
 
However, IL1α export does not require p40 Syt1 compared to FGF1export. 
Kumar group has proposed that, it might indicate another unknown cytosolic protein is 
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playing this role instead of p40 Syt1 in the IL1α release complex. The p40 Syt1 protein is 
involved in other proteins stress-induced export like syntaxin 2 (epimorphin) in addition 
to annexin II. The export of IL1β and FGF2 might require S100A13, p40 Syt1, SK1, 
annexin II, and Cu2+ but this assumption need to be further clarified. Cu2+ might be 
involved in the association of the members of multiprotein aggregates involving FGF1, 
IL-1α, S100A13 and p40 Syt1 that are all Cu2+-binding proteins. Cu2+ induces FGF1 
homodimer but not FGF2 even though two of the three cysteine residues present in FGF1 
are conserved in FGF216. In addition, Cu2+ might participate in the non-classical release 
of angiogenic and pro-inflammatory polypeptides as many studies have demonstrated 
angiogenic and pro-inflammatory effects of Cu2+. It has been noted that attenuation of the 
stress-induced release of IL-1α and FGF1, as well as of S100A13 when co-expressed 
with IL-1α or FGF1 is achievable via the depletion of intracellular free Cu2+ through 
continuous application of a specific chelate, tetrathiomolybdate (TM). Therefore, the 
stress-induced Cu2+-dependent assembly of IL-1α and FGF1 multiprotein release 
complexes is indeed a requirement for the non-classical export of these proteins in vitro 
as demonstrated by different studies41, 42. 
Cell Signaling and Growth Factors  
In multicellular organisms, cellular communication between millions of cells is 
critical function for allowing different cells work together. Cellular responds to 
environmental changes are essential for regulating biological pathways. Cellular 
commination can be taken place by sending different molecules including proteins, lipid, 
gas, and polypeptide43. The process of cell signaling is either by passing molecules 
between two adjacent cells through the gap junctions or by releasing growth factors44, 45. 
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Cellular response occurs when a cell recognizes a signal that comes from either the 
environment or produced by another cell, via a receptor; then receptor-ligand complex 
generates signal transductions46. In multicellular organisms, the growth factors are 
important cell signaling molecules because growth factors provide different cell-to-cell 
communication mechanisms including endocrine signaling (long distance interaction), 
paracrine signaling (nearby interaction), and autocrine signaling (self-interaction). 
Growth factors carry information to trigger gene expression, cellular differentiation, and 
mitogenesis47.  They help promoting cellular growth and cellular productions in response 
to many environmental changes. Growth factors are usually small proteins known as 
cytokines48. Cytokines are secreted proteins that have specific roles on cellular 
interactions and communications.  
Based on the type of secreting cells, there are many kinds of cytokines including 
lymphokines (secreted by lymphocytes), monokines (secreted by monocytes), and 
interleukins (secreted by leukocytes and interact with leukocytes). Interleukins are a set 
of proteins that thought to be particularly secreted by the leukocytes. Interleukins play 
important functions in cellular communication, cellular growth, and immune responses. 
They are categorized into various families based on the homology of their amino acids 
sequences, targeting specific receptors, and performing similar functions49. Interleukin-1 
family (IL-1) was the first group of interleukins that was identified50. IL-1 family is a 
pro-inflammatory cytokine with several effects on cellular proliferation, differentiation 
and immune reactions. Nine members are under the name of IL-1 family51. Among many 
other cytokines, IL-1 family of cytokines is primarily mediated with inflammatory 
response against several harm irritations52.  
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Figure 3: Interleukin 1 family members tree. 
Even though members of IL-1 family of cytokines are associated with innate immunity 
response, many inflammatory disease such as degenerative diseases are linked to 
uncontrolled secretion of some interleukin-1 family members53.    
Interleukin 1 alpha (IL-1α) 
In 1974, two different isoelectric forms of IL-1 with two different molecular 
weights were reported by Dinarello54. An acidic human form with molecular weight of 
31,000 Da corresponding to IL-1α and another neutral human form corresponded to 
human IL-1β with a molecular weight of 17,000 Da.  Interleukin-1α (IL-1α), is one of the 
molecules that have been recognized long time ago; still a lot of data about its role in 
various diseases are vague. The term of interleukin has roots started in the early 1940s, 
when sterile pus was injected into rabbits causing a fever55. Many years later, a group of 
researchers conducted an in vivo study on white blood cells investigating the causative 
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agent(s) that induced the fever56. At that time, they found a molecule acted as a 
thymocyte mitogen, so the term endogenous pyrogen was used (EP)57. Later, in the 
second international lymphokine workshop that held in Interlaken, Switzerland, the term 
interleukin came up in honor of the city where the meeting was conducted58. IL-1α is one 
of the leaderless proteins that lack a signal peptide. This means its secretion is aimed 
without endoplasmic/Golgi system59. IL-1α is an exceptional type of cytokine as it 
always presents inside all resting non-hematopoietic cells as well as hematopoietic cells 
in both healthy and unhealthy situations60. In addition, it is usually up regulated during 
hypoxic situations. Moreover, it has a vital role in necrosis that mediates early 
inflammatory reactions triggered by its release from damaged tissues61. It acts through 
recruitment of neutrophils to the damage site, besides its induction by different released 
cytokines and chemokine from inflammatory cells in the surrounding tissue. It has a 
unique role in multiple inflammatory diseases. Moreover, IL-1α plays key roles in many 
cellular processes such as cellular proliferation, angiogenesis, and tumor growth. IL-1α is 
known to act as transcription factor inside the nucleus to induce cells to make many 
mRNA expressions of other cytokines such as IL-6 and IL-8 and itself as positive 
feedback control (Figure 2). Also, it acts as secreted protein outside the cells binding to 
specific receptors62. Furthermore, some studies showed that IL-1α is expressed as 
membrane bounded protein works as cancer cells surveillance62. IL-1α can increase 
immunogenicity against tumor cells and serve as anti-tumor immune. Upon membrane 
bound form, IL-1α can be glycosylated and placed on the cell membrane of activated 
cells like monocytes or macrophages, and other cells, by a lectin-like association to 
induce inflammation63, 64. This membrane-associated IL-1α activates IL-1R1 on target 
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cells, such as endothelial cells and T-cells, and in fibroblasts. Membrane-associated IL-
1α has been recognized as main cytokine that potentiates stimulation of other cytokines in 
the senescence-associated secretory phenotype (SASP) response. This response involves 
secretion of pro-inflammatory cytokines, such as IL-6 and IL-865. On the other side, when 
a tumor cell reaches senescent, the resulting inflammatory response can promote 
invasiveness66-67. Also, when cancer cell dies, precursor IL-1α is released acting as 
inflammatory inducer that may lead to tumor invasiveness and angiogenesis62, 68. 
Interleukin-1  expression 
Interleukin-1 is expressed in many different cells at steady state in both healthy and 
non-healthy condition, but its secretion level is increased in response to stressed 
conditions. In contrast to other interleukins, IL-1 can be generated by endothelial cells 
as well as epithelia cells57, 69, 70.  
Interestingly, IL-1 gene contains a binding site for Sp1 transcription factor that 
is known to regulate housekeeping genes instead of canonical TATA and CAAT 
regulatory regions71. IL-1 expression varies based on the type of the cells. For example 
in monocytes, the regulation involves the long noncoding RNA-AS IL-1 transcription 
factor that is partially complementary to IL-1 mRNA72. However, in human CD4+ T 
cells, the hypo/hyper methylation of CpG nucleotides in the transcription initiation site 
regulates IL-1 gene expression73. The IL-1α gene is located on the long arm of 
chromosome 2 end to end to the IL-1β gene74. The first IL-1 cDNA was cloned in 1984 
from two different species, human blood monocyte and a mouse cell line75, 76. The IL-1 
gene product in those sources was different as the human product was neutral and the 
other was acidic54. The IL-1 α gene primary product is a 271 amino acid precursor then it 
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is processed to produce a shorter mature protein, which is the carboxyl terminal end of 
the precursor27.  
Interleukin 1 alpha structure 
After removing the pro-piece mature form of interleukin 1 alpha is 162 amino 
acids protein with 18.5 KDa. It is entirely made of twelve antiparallel β-sheets. In the 
center, six-stranded β-barrels are arranged to be closed to another six β-strands forming a 
bowl like structure. At the N-terminus, a short β-strand that composes 6-18 then another 
short β-strands of amino acids 97-99. Amino acids 101-105 make two turns. Three-fold 
structural symmetry in the protein core.  
 
Figure 4: shows the three-dimensional structure of interleukin 1 alpha. Twelve anti 
parallel beta strands that make the bowl shape at the center of protein core16.    
 
IL-1α receptors  
IL-1α, IL-1β and IL-1Ra exhibit the biological functions by specific binding to 
IL-1R177, 78. Various human cells such as T-cells and fibroblasts express the 80 KDa IL-
1R1. The extracellular domain of IL-1R1 composes of 319 amino acids assembled in 
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three Ig-like domains79. Also, the cytoplasmic domain that has strong homology to toll 
like receptor comprises of 215 amino acids80. IL-1α can bind to IL-1R2 with no effects. 
Interestingly, IL-1R2 is 60 KD and it is shorter than IL-1R181. This observation explains 
that IL-1R1 and IL-1R2 are produced from different genes. It is believed that IL-1R2 
works as decoy to control and regulate the biological functions of IL-1α and IL-1β82. The 
extracellular domain of IL-1R2 also consists of three immunoglobulin domains. IL-1R2 
contains a short intracellular cytoplasmic tail that is 29 amino acids long. This indicates 
that two IL-1 receptors interact with different signal transduction pathways83. IL-1R2 is 
expressed by a number of cells including B and T-lymphocytes. Upon exerting the 
biological roles, IL-1α binds with high affinity to the IL-1RAcP making tetramer protein 
complex with IL-1R181. The binding reaction requires firstly IL-1α causes 
conformational changes to IL-1R1 upon binding then secondly the conformational 
changes in the IL-1R1 allow IL1-RAcP to bind to the IL-1/IL-1R1 complex leading to 
signal transduction. IL1-RAcP provides high stability signals that increase IL-1 binding 
affinity84.  
IL-1 α signaling  
IL-1 α signaling is activated in response to infection, tissue injury or stress85. 
Mitogen-activated protein (MAP) kinase p38, extracellular signal-regulated kinase 1/2 
(ERK1/2), c-Jun N-terminal kinase and nuclear transcription factor κB (NFκB) are the 
main pathways that are activated by IL-1 α86, 87. The hetero-tetramer complex of IL1-
RAcP and IL-1R1 /IL-1α complex is required for increasing binding affinity and to 
introduce the signal transduction. The cytoplasmic domains of IL1-RI and IL1-RAcP 
belong to the Toll like receptor (TLR) family reported as Toll/interleukin-IL-1 (TIR). The 
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creation of the IL-1/IL-1RI /IL1-RAcP complex enables recruitment of the adapter 
molecule MyD88, which also contains TIR domain, to the TIR domains of IL1-RI and 
IL1-RAcP81. Binding of IL-1 with the IL1-RII decoy receptor leads to loss of the TIR 
domain, which is required for signal transduction. Subsequently, the serine/threonine of 
IL-1 Receptor Associated Kinase IRAK-1, IRAK-2 and the IRAK-4 are recruited and 
activated by MyD88. In a resting state, IRAK-1 is associated with a Toll-interacting 
protein (Tollip)87. The phosphorylation of Tollip is required for IRAK-1 activation. These 
multiple kinases cause the recruitment and activation of tumor necrosis receptor-
associated factor-6 (TRAF6)88. The IRAK-1/TRAF6 complex interacts with transforming 
growth factor β-activated kinase-1 (TAK-1) within the cytoplasm, which then 
phosphorylates the IκB kinase (IKK) complex. The degradation of the phosphorylated 
IKK is leading to translocate NFκB to the nucleus and activate gene expression89. 
Alternatively, the interaction between TRAF6 and the TRAF associated protein named 
evolutionarily conserved signaling intermediate in Toll pathways (ECSI), causes 
activation of c-Jun through the Map kinase/JNK signaling cascade90. 
Role of IL-1 α in pathogenesis of various diseases 
Role of IL-1α in inflammation and autoimmune diseases 
IL-1α is associated with various scopes of many diseases and causes a sterile 
inflammatory response. Also, there are increased levels of IL-1α in synovial fluid of 
rheumatoid arthritis patients91, 92. In psoriasis, IL-1α amplified level is found to correlate 
positively with disease severity and keratinocytes express IL-1α constitutively93. The 
presence of IL-1α in resting cells constantly can explain why IL-1α has emerged as a key 
cytokine in eliciting sterile inflammation. Toll like receptor helps to distinguish between 
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self and non-self-molecules by binding to pathogen associated molecular pattern 
(PAMPs)94. On the other hand, tissue injury requires identifying alarm signals to approve 
a sterile environment. In this case, alarm signal is precursor IL-1α that activates 
inflammatory responses against dead cells95, 96. On the contrary, in cells directed to the 
apoptotic pathway, IL-1α stays inside the nucleus, and fails to initiate an inflammatory 
response97, 98. This retention of IL-1α ensures by binding chromatin to nuclear IL-1 α89, 97. 
This linkage is tight, that reduce the mobility of IL-1α preventing its release97, 99. 
Additional significant study showed that IL-1 α released from dead cells lead to 
activation of IL-1R1100. In experimental models to study peritonitis in mice, an 
inflammatory response and neutrophil infiltration occurred in an IL-1 α dependent 
manner by the injection of cell lysate in the peritoneal cavity101. It is believed that IL-1α 
was mainly released from necrotic cells and the surrounding mesothelial cells secrete C-
X-C motif chemokine ligand 1 (CXCL1) through an IL-1R1-Myd88 signaling dependent 
manner102.  
Correlation of IL-1α with neurodegenerative diseases  
Furutani et al. in 1986 had paved the way to new discovery in the field of 
inflammatory diseases when the sequence and the organization of the IL1α gene was 
published103. For instance, in systemic sclerosis (SSc), which is a known inflammatory 
disease, IL-1α is up regulated in fibroblast cells. This up regulation triggers an 
inflammatory process involving IL-6 and procollagen leads to worsening the auto-
inflammation and fibrosis associated104, 105. Fibroblast cells obtained from SSc biopsies 
showed an increased level of transcription of IL-1α106. This activated IL-1α increases 
inflammation107. Alzheimer’s disease (AD) is one of the neurodegenerative diseases, in 
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which an inflammatory process causes loss of neurons. Biopsies on postmortem human 
brain tissue sections from AD patients exhibited an elevated levels of IL-1α in the 
temporal lobe108. A characteristic finding in all AD biopsies is the presence of Beta-
amyloid plaques that correlates with IL-1 α expression in microglia cells109, 110, 111, 112, 113. 
IL-1α genetic variation was found to play a role in the occurrence of periodontal disease, 
an inflammatory disease, which is associated with bacterial plaque due to poor oral 
hygiene, but is also common among smokers and diabetic patients114, 115. In non-smokers, 
the disease noticed to be associated with elevated IL-1α protein levels and the T allele at 
the −889 position116, 117.  
IL-1α role in tumor  
There are a lot of pro-inflammatory cytokines that contribute to the process of 
carcinogenesis118, 119. The role of IL-1 in tumor progression and invasiveness has been 
extensively a focus of many researchers. Mutually IL-1 agonistic molecules (IL-1α and 
IL-1β) can promote tumor invasiveness, metastasis and chemical-induced carcinogenesis 
through inflammatory responses they induce if they are present in their secreted form. A 
lot of data clarified the fundamental role that IL-1 molecules play in the development of 
tumor-induced angiogenesis120, 121. Such as, IL-1α and recombinant IL-1β are well-known 
angiogenic promoting factor. Though, the effects of micro-environmental IL-1α on 
melanoma development in mice were significantly less than the effects of micro-
environmental IL-1β.  
Chronic inflammation has been linked with malignant transformations122, 123. 
Many studies have observed that secretory form of IL-1α is a well-recognized pro 
inflammatory cytokine in tumor microenvironment that fasten tumor growth and 
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invasiveness, whereas membranous form of IL-1α when present in tumor cells lead to 
trigger destruction of this cell by immune-mediated mechanisms124, 125. Early infiltration 
by macrophages and CD8+ T cells lead to regression in tumors expressing IL-1 α in vitro. 
On the contrary, in vivo absence of CD8+ T cells but not CD4+ T cell abolishes 
regression of IL-1α- positive fibrosarcoma tumors. Long-term specific immune memory 
protects mice against a challenge with wild type cells (IL-1α-negative). The mechanism 
by which IL-1α expressing tumor cells cleared by the immune system has been a focus of 
a lot of researchers. Recently, it has been hypothesized that membrane-associated IL-1 α, 
may possibly serve as a second co-stimulatory signal or focused adjuvant for their direct 
activation when ligates to IL-1R1 on effector cells, such as CTLs. Additional, antigen 
presentation by the tumor cells themselves can be triggered by tumor cell-associated IL-
1α through IFNα- induced MHC class II expression, or via cross-presentation by 
professional APCs. The eradication of IL-1α-positive fibrosarcomas might be through 
non-adaptive effector cells, such as NK cells and activated macrophages. Membrane- 
associated IL-1α immunotherapeutic effects were tested as anti-tumor in tumor-bearing 
mice. Therefore, Mitomycin-C-treated IL-1α expressing cells that introduced at the 
critical “therapeutic window” caused regression of wild type fibrosarcoma cells124. 
Similarly, regression of invasiveness of malignant lymphoma was shown if cell-
associated IL-1α was expressed. Also, invasive T lymphoma cells, which metastasize to 
the spine showed regression if transient cell-associated IL-1α was expressed126. This 
shows that a difference present between cell-associated IL-1α and secreted IL-1α. In case 
of pancreatic adenocarcinoma, tumor-associated IL-1α was found to be the triggering 
factor of tumor growth. The binding of IL-1α to its receptor on cancer-associated 
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fibroblasts stimulates the production of inflammatory factors. For example, neutralization 
of IL-1α signaling was used to reduce these inflammatory effects. Extracellular IL-1α 
that was released from dying cells caused these effects127. IL-1α seems to be expressed in 
different varieties of tumors. It acts with IL-1β and MyD88 to increase reactive oxygen 
and nitrogen species, COX-2, phosphorylated NF-kB inhibitor (IkB) and stress-activated 
protein kinase/c-jun-NH(2)-kinase, inducing promotion of tumor progression128. 
Undoubtedly, IL-1 α behaves in different ways in tumor cells depending on whether it is 
secreted or being intracellular.  Secreted form IL-1α might induce inflammation and 
favor tumor progression, as does IL-1β. Intracellular form, IL-1α is displayed on the 
membrane and induces anti-tumor cell immunity that might limit growth and regression. 
Certainly, IL-1α deficient mice displayed a delay in tumor growth and an impaired 
angiogenic response. Additionally, the role of IL-1α in pancreatic cancer progression 
might be through promoting angiogenesis and in prostate cancer it might be due to up- 
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The efficiency of protein purification is vital to the development of 
pharmaceuticals and to the evolution of biomedical research. The cost of the most 
common techniques used for purification of recombinant proteins constitutes a significant 
portion of the multi-billion-dollar pharmaceutical industry, particularly due to the 
conversion of some proteins into inclusion bodies when using a heterologous host.    
The investigations into more cost-effective and less labor-intensive methods for 
the purification of recombinant proteins are important to receive higher yields at a 
lowered monetary investment.  Rubredoxin (Rd) is a 53 amino acid long protein, which is 
an ideal tag due to its low molecular weight (7kDa), red color for easy identification, and 
extreme thermostability. The Rd protein is the tag used in the purification of IL-1α, D2 
(FGF1 receptor domain), and the anti-fungal peptide. This novel tag has been named 
ARK-RUBY-tag which stands for Arkansas Rubredoxin purification tag and ruby refers 
to the red color of the protein. The tag was able to keep all recombinant proteins in 
soluble form. The protein expression was monitored by the presence of the red color.  
Since the main subject of this project is IL-1α, the tag and the fusion protein were 
examined thoroughly, which shed light on the main properties and characterization of the 
tag. Utilizing the tag, IL-1α was purified in high yields and displayed good bioactivity.  
The Ark-RUBY- recombinant proteins showed significant thermal stability.  





Recombinant DNA technology and the production of recombinant proteins have 
evolved in the pharmaceutical and biotechnological industry through the introduction of 
drug-based protein production for use in healthcare1.  Due to unsatisfactory yields of 
bioactive proteins isolated from their natural sources, the large-scale production of 
recombinant proteins in suitable heterologous host systems have been of significant 
interest2, 3. In particular, Escherichia coli (E. coli) has been extensively used as a suitable 
heterologous host to facilitate recombinant protein expression because it is compatible 
with various cloning vectors, its amenability to genetic modification(s), high 
transformation efficiency, and its adaptability for rapid high-density cultivation under 
variety conditions4-6. However, high yield of recombinant protein expression in E. coli 
causes protein aggregation and inclusion bodies (IBs) formation, which is a common 
major problem in the large-scale production of recombinant proteins in heterologous host 
systems7, 8. IBs are dense intracellular bodies mostly consisting of aggregated 
recombinant proteins that are misfolded and hence are functionally inactive9. Recovering 
of target recombinant proteins which form inclusion bodies involves multiple steps such 
as, isolation of pure inclusion bodies, solubilization of inclusion bodies, refolding of 
solubilized recombinant protein(s) and purification of refolded proteins using different 
various chromatographic techniques10-12. Inclusion bodies are highly specific aggregates 
and mostly consist of the recombinant protein of interest13, 14. Owing to the multiple steps 
involved, the yields of the pure and bioactive target recombinant proteins from IBs is 
often very low15, 16. Biotechnology and pharmaceutical companies incur huge losses 
amounting to millions of dollars in lieu of the multiple, cumbersome, time-consuming, 
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and labour-intensive steps involved in recovery of recombinant proteins that are 
biomedically significant or serve as potential therapeutics against a wide array of 
diseases5, 17. In this context, there is immense commercial interest in designing methods 
to thwart the overexpression of recombinant proteins, of biomedical importance, as 
inclusion bodies. The target fusion protein is overexpressed and the specific binding 
characteristics of the affinity tag are exploited to selectively purify target fusion proteins 
by employing a relevant affinity chromatographic technique18, 19. The affinity tag is 
subsequently separated from the target protein by selective cleavage of the target fusion 
protein using restriction proteases20. A number of fusion protein tags including, 
glutathione S-transferase (GST)21, thioredoxin A (TrxA)22,  maltose-binding protein 
(MBP)23, poly histidine (His)24, green fluorescent protein (GFP)25, streptavidin, 
ketosteroid isomerase (KSI)26, and heparin binding (HB)27 peptide have been successfully 
used for the overexpression and purification of recombinant proteins in different 
expression hosts including E. coli. However, use of these purification tags has one or 
more significant limitations such as,  i) higher molecular weight of affinity tags which 
reduces column capacity28, ii)  poor solubility of affinity tag(s)24, iii) high costs of affinity 
resins29, iv) low expression yields30, v) interference with the folding and functional 
properties of target recombinant proteins, vi) involvement of expensive mobile phase 
buffers28, and vii) poor temperature stability and susceptibility to proteases secreted by 
expression hosts31. In this context, there is significant interest toward the development of 
a protein affinity tag that renders recombinant protein overexpression and purification 
simple, efficient, versatile, and cost-effective32, 33.    
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Rubredoxin (Rd) is a small molecular weight monomeric non-heme iron-sulfur 
protein (7 kDa), composed of 53-58 amino acids34, 35. Rd has been isolated from several 
thermophilic and mesophilic organisms36. Rd was first identified from Pyrococcus 
furiosus (PfRd), a hyperthermophilic anaerobic archaeon able to thrive in oceanic hot 
springs at temperatures approaching 100°C37, 38. Rd protein has an exceptionally high 
thermal stability (Tm > 90°C)36.  Rd from Pyrococcus furiosus is the most stable protein 
which has currently been identified39. Rd belongs to the α and β class of proteins 
consisting of 2 α-helices and 2 or 3 antiparallel β-strands40. The active site of Rubredoxin 
contains an iron-sulfur cluster [Fe2S2] wherein an iron ion is coordinated by the sulfurs of 
four cysteine residues of the protein40. The expression of recombinant proteins in E. coli 
was monitored using the absorption of Rd from Thermotoga maritima at 380 nm41. 
Overexpression and purification of recombinant proteins were achieved using rubredoxin 
from a mesophilic anaerobic bacteria, Desulfovibrio vulgaris42. However, using this 
technique was limited by the difficulty to prevent the formation of inclusion bodies due to 
the lower thermal stability and slower folding rates of this bacterial strain.  Moreover, 
there was loss of the iron sulfur center, responsible for the red color formation, due to the 
lower stability of the rubredoxin from Desulfovibrio vulgaris during large-scale 
production of recombinant proteins41.  Interestingly, Rubredoxin from Pyrococcus 
furiosus shares about 63 % amino acid sequence identity with its mesophilic 
counterpart43, 44. In this context, in the present study, a novel polyhistidine Rd purification 
tag was designed, which I would prefer to hitherto name as Ark-RUBY (Arkansas 
Rubredoxin purification tag), for the soluble overexpression of recombinant 
protein/peptides in heterologous hosts. Linking the polyhistidine tag to Rd is also 
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expected to aid in the purification of Ark-RUBY fused target protein/peptide(s) using 
nickel/cobalt affinity chromatography45-47. Also, the amino acid sequence of Rd does not 
contain methionine. This aspect will facilitate the cleavage of the Rd-fused methionine-
less recombinant protein/peptide(s) in a cost-effective manner using cyanogen bromide 
(CNBr), a reagent that specifically cleaves polypeptide chains at the C-terminal end of 
methionine48-50.   
Experimental methods 
pUARC-RUBY expression vector and construction and expression of the Ark-
RUBY-IL-1α, Ark-RUBY-D2 and Ark-RUBY-AF gene  
The designed expression vector with novel peptide fusion partner to Rd 
(Rubredoxin, little iron-Sulfur protein: originated in P. furiosus) for E. coli heterologous 
expression is outlined (Figure 1).  
Figure 1: Map of pUARC-RUBY plasmid: The rubredoxin gene with 9-histidine tag 
cloned under tac promoter. The carboxyl terminus of RD gene sequence encodes specific 
thrombin site with overlapping BamHI and other MCS in pGEX series vector. The 
segment map of promoter, rbs, RD and MCS are highlighted below. The total sequence 
of pUARC-RUBY is 4500bp. 
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As depicted in illustration, the higher copy number origin, Ori is with tac promoter, as 




GAAGAT-3’) was used with unique 9-histidine tag encoded by 
(5’CATCATCACCATCACCATCACCATCAC3’) the fusion partner at the amino 
terminus. The specific thrombin cleavage site of LVPRGS encoded by 
(5’CTGGTGCCGCGTGGATCC-3’) was used as part of multi-cloning site, MCS 
(besides BamHI, underlined endonuclease sequence, other selective endonuclease sites at 
MCS are: NdeI, HindIII, XbaI, XhoI and NotI) for single step cloning of any host protein. 
The vector design originated by inserting the synthetic gene sequence (Genscript Inc.) 
with the GST replacement, which was inserted using BtgI and NotI restriction enzymes. 
The DNA sequence was verified by sequencing. The model host protein, interleukin-1α 
(IL-1alpha, commonly known as hematopoietin 1 is a cytokine of the interleukin 1 family 
which, in humans, is encoded by the IL1A gene) was cloned into pUARC-RUBY by 
utilizing the MCS, namely the NdeI and XhoI cloning sites in the expression vector. The 
final sequence of this construct was verified by DNA sequencing. Polymerase chain 
reaction (PCR) was used to amplify gene specific primers, which code for the Ark-
RUBY-IL-1α. The vector that contains the 9×His-Ark-RUBY-IL-1α was then 
transformed into E. coli cells. After obtaining confirmation of the nucleotide sequences, 
protein was overexpressed in BL21(pLysS) E. coli cells cultured in 1 L of terrific broth 
(TB) medium containing 500 μg/mL ampicillin and 500 μg/mL chloramphenicol. The 
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induction of protein was accomplished by the addition of IPTG (final concentration 0.5 
mM) when the OD at Abs 600 of the growing culture had reached 0.6. After 4 hours 
incubation of the culture at 37 °C with agitation at 250 rpm, the cells were harvested and 
lysed by ultra-sonication. The cell lysate was separated from the cell debris using ultra 
centrifugation at 19,000 rpm. The same methods were followed for the expression of 
Ark-RUBY-D2 and Ark-RUBY-AF by using Ark-RUBY-D2 and Ark-RUBY-AF genes, 
respectively (Figure 1 & 2 panel A, B, & C & Figure 3). 
Negative staining Transmission electron microscope  
Bacterial pellets of 6×His-IL-1α, Ark-RUBY-IL-1α, 6×His-D2 and Ark-RUBY-
D2 were overexpressed in E. coli cells. The treated E. coli cells were resuspended with 10 
mM PBS at pH-7.2.  Each resuspended solution was spotted onto a Formvar and carbon-
coated copper grid (Electron Microscopy Sciences, USA). A 2% solution of Uranyl 
acetate dissolved in distilled water (pH 4.2 to 4.5) was used to negatively stain the 
samples. Uranyl acetate solution was filtered through a 0.22 µm filter before use. After 2 
minutes, the remaining solution was removed with filter paper and the samples were 
dried with filter paper. TEM images were taken at different magnifications by using high 
resolution transmission electron microscopy (Jeol-HRTEM-2011, USA) with an 
accelerating voltage of 80-100 kV. 
Purification of recombinant Ark-RUBY-IL1α and IL-1α  
Nickel (Ni2+)-Sepharose column (Amersham Biosciences, USA) was used for 
purification of Ark-RUBY-IL-1α. The clear bacterial cell lysate was centrifuged for 25 
minutes at 19,000 rpm 4°C.  Then the supernatant was loaded on to a nickel (Ni2+)-
Sepharose column, and then the column was washed with 10mM PBS (phosphate 
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buffered saline) at pH 7.2.  A stepwise gradient of imidazole was used to elute all 
proteins bound to the Ni2+-Sepharose column. The elution of proteins was monitored by 
absorbance measured at 280 nm. Fractions collected at a concentration of 250 mM 
Imidazole contain the Ark-RUBY-IL-1α protein. At that point, pure Ark-RUBY-IL-1α 
was incubated with 100 NIH units of thrombin for 12 h (at 37°C) to cleave the affinity 
tag. After that, thrombin cleavage products were reloaded onto a Ni2+-Sepharose column. 
In order to elute IL-1α, the column was washed thoroughly with 10 mM PBS at pH 7.2 
and a stepwise imidazole gradient was used. IL-1α was eluted in the 250 mM imidazole 
fraction. The 250 mM Imidazole fraction was subjected to desalting by ultrafiltration 
using a 10 kDa cut-off membrane. Then, the bound Ark-RUBY tag was eluted in 250 
mM and 500 mM imidazole fractions. At each step, SDS-PAGE was performed to check 
the purity. At the final point, IL-1α concentration was estimated by Abs 280 nm, using 
the extinction coefficient value (Σ280 = 21430 M-1 cm-1) that is calculated from the 
amino acid sequence of the protein.  
Western-blot detection method  
Purified Ark-RUBY-fusion proteins were resolved on 15% SDS-PAGE under 
reduced conditions. The gel containing the fusion proteins was subjected to blot transfer 
for western blot.  Blotted/spotted nitrocellulose membrane was blocked using 5% skim 
milk in 1x TBS-T (10mM tris, 100mM NaCl, 0.05% Tween-20; pH 7.4) at room 
temperature for 1hr. Subsequently, the membrane was washed with 0.2% BSA in 
1XTBS-T and the primary antibodies raised in goat against the His tag was added at 
1:2500 dilution and incubated overnight at 4°C. Secondary antibody conjugated with 
alkaline phosphatase that detects the IgG goat antibody was added to the membrane at 
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1:2500 dilution and incubated for 2 hours at 4°C. The band on the membrane was 
detected using the NBT/BCIP (Nitro-blue tetrazolium/5-Bromo-4-chloro-3-indolyl 
phosphate) substrate within 60 seconds of exposure. 
Purification of Ark-RUBY-AF by Heat treatment  
The E. coli bacterial lysate was subjected to heat treatment at increasing 
temperatures in a water bath from 25 °C to 90 °C (at 5°C intervals) for 10 minutes. All 
samples were centrifuged at 13,000 rpm for 5 minutes to separate the aggregates from the 
cell lysates. The results were revealed by SDS-PAGE gel for both samples (pellets and 
lysates).   
Far UV-Circular Dichroism study  
All far UV-circular dichroism (CD) measurements were performed on a Jasco-
1500 spectrophotometer at 25 °C using a quartz cell with 1 mm path length with a scan-
speed of 100 nm/sec. Each spectrum was an average of 3 scans. The concentration of 
Ark-RUBY, Ark-RUBY-IL-1α and purified IL-1α were maintained as 20 μM. The final 
spectrum was obtained after the subtraction of the corresponding buffer spectrum. 
Equilibrium unfolding  
The equilibrium unfolding experiments were performed on a Jasco-1500 
spectrophotometer at 5°C intervals by using a concentration of Ark-RUBY- IL-1α, 
purified IL-1α, and Ark-RUBY of 20 μM in 10 mM PBS at pH7.2. The unfolding process 
of the proteins was monitored through changes of protein structure in the far-UV region 
(190-250nm). Required background corrections were made for all spectra.  
Biological activity assay  
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Splenocytes were isolated from 6-12 weeks old C57BL/6J mice. The mice were 
housed under pathogen free conditions and maintained in the microisolator cages. The 
Institutional Animal Care and the Committee of the University of Arkansas approved for 
raising of the mice. Animal care complied with the recommendations of the Guide for 
care and use of Laboratory Animals (National Research Council). Dulbecco’s Modified 
Eagle’s Medium (DMEM), RPMI 1640, Dulbecco’s Phosphate Buffered Saline (PBS), 





Figure 2: Panels- A, B, and C represent Escherichia coli codon optimized nucleotide 
sequence and single letter coded amino acid sequence of Ark-RUBY-IL-1α, Ark-RUBY-
D2, and Ark-RUBY-AF [nucleotide sequence and corresponding amino acid sequence of 
Ark-RUBY tag shown in red, thrombin and TEV cleavage site shown in blue, target 








IL1a               1 ------------------------------------------------      0  
                                 
Seq                1 TNNTNNGCGGNANATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAA     50 
 
IL1a               1 --------------------------------------------------      0 
                                                                        
Seq               51 GGAGATATACATATGCACCACCACCACCACCACATGGCGAAATGGGTTTG    100 
 
IL1a               1 --------------------------------------------------      0 
                                                                        
Seq              101 CAAGATTTGCGGCTATATTTACGACGAAGATGCTGGCGACCCGGACAACG    150 
 
IL1a               1 --------------------------------------------------      0 
                                                                        
Seq              151 GCATTAGTCCGGGCACCAAATTTGAAGAACTGCCGGATGACTGGGTCTGC    200 
 
IL1a               1 --------------------------------------------------      0 
                                                                        
Seq              201 CCGATCTGTGGTGCGCCGAAAAGCGAATTTGAAAAGCTGGAAGATCTGGT    250 
 
IL1a               1 -------GGATCCATGAGGTCAGCACCTTTTAGCTTCCTGAGCAATGTGA     43 
                            ||||||||||||||||||||||||||||||||||||||||||| 
Seq              251 GCCGCGTGGATCCATGAGGTCAGCACCTTTTAGCTTCCTGAGCAATGTGA    300 
 
IL1a              44 AATACAACTTTATGAGGATCATCAAATACGAATTCATCCTGAATGACGCC     93 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              301 AATACAACTTTATGAGGATCATCAAATACGAATTCATCCTGAATGACGCC    350 
 
IL1a              94 CTCAATCAAAGTATAATTCGAGCCAATGATCAGTACCTCACGGCTGCTGC    143 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              351 CTCAATCAAAGTATAATTCGAGCCAATGATCAGTACCTCACGGCTGCTGC    400 
 
IL1a             144 ATTACATAATCTGGATGAAGCAGTGAAATTTGACATGGGTGCTTATAAGT    193 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              401 ATTACATAATCTGGATGAAGCAGTGAAATTTGACATGGGTGCTTATAAGT    450 
 
IL1a             194 CATCAAAGGATGATGCTAAAATTACCGTGATTCTAAGAATCTCAAAAACT    243 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              451 CATCAAAGGATGATGCTAAAATTACCGTGATTCTAAGAATCTCAAAAACT    500 
 
IL1a             244 CAATTGTATGTGACTGCCCAAGATGAAGACCAACCAGTGCTGCTGAAGGA    293 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              501 CAATTGTATGTGACTGCCCAAGATGAAGACCAACCAGTGCTGCTGAAGGA    550 
 
IL1a             294 GATGCCTGAGATACCCAAAACCATCACAGGTAGTGAGACCAACCTCCTCT    343 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              551 GATGCCTGAGATACCCAAAACCATCACAGGTAGTGAGACCAACCTCCTCT    600 
 
IL1a             344 TCTTCTGGGAAACTCACGGCACTAAGAACTATTTCACATCAGTTGCCCAT    393 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              601 TCTTCTGGGAAACTCACGGCACTAAGAACTATTTCACATCAGTTGCCCAT    650 
 
IL1a             394 CCAAACTTGTTTATTGCCACAAAGCAAGACTACTGGGTGTGCTTGGCAGG    443 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              651 CCAAACTTGTTTATTGCCACAAAGCAAGACTACTGGGTGTGCTTGGCAGG    700 
 
IL1a             444 GGGGCCACCCTCTATCACTGACTTTCAGATACTGGAAAACCAGCTCGAGC    493 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq              701 GGGGCCACCCTCTATCACTGACTTTCAGATACTGGAAAACCAGCTCGAGC    750 
 
IL1a             494 ACCACCACCACCACCACTGA------------------------------    513 
                     ||||||||||||||||||||                               
Seq              751 ACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAA    800 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq              801 GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG    850 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq              851 GGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATAT    900 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq              901 CCGGATTGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGG    950 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq              951 GTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCG   1000 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq             1001 CCCGCTCNTTCGCTTTCTTCCCTTCNTTCTCGCCACGTTCGCNGCTTTCC   1050 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq             1051 CCGTCAAGCTCTAATCGGGGCTCCCTTTAGGGTTCCGGATTTAGTGCTTA   1100 
 
IL1a             514 --------------------------------------------------    513 
                                                                        
Seq             1101 CGGCACTCGACCCCAAAAAACTNGATAGGTGATNNNNCGTANNGGNNNAN   1150 
 
IL1a             514 ---------------------------------------------    513 
                                                                   
Seq             1151 NNNGGATAGACGNNNTTTCNNCNTNNCCNTTGGNNTNNNGNTNNT   1195 
Figure 3: Represents experimental confirmation of the DNA sequence of human IL-1α. 
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Results & Discussion 
Ark-RUBY prevents the formation of Inclusion bodies Ark-RUBY-IL-1α and Ark-
RUBY-D2-FGFR1 are each overexpressed in E. coli as soluble proteins. In contrast, 
6×His-IL-1α and 9×His-D2-FGFR1 were completely expressed as insoluble inclusion 
bodies. Transmission Electron Micrographs (TEM) of E. coli cells, induced by Isopropyl 
β-D thiogalactoside show that 6-His-IL-1α and 9xHis-D2-FGFR1 are overexpressed as 
dense and opaque inclusion bodies (Figure 4, Panel A and C). However, TEM data of the 
E. coli cells overexpressing Ark-RUBY-IL-1α and Ark-RUBY-D2-FGFR1 are mostly 
clear and do not show formation of inclusion bodies (Figure 3, Panel B and D).  
 
Figure 4: Panels-A, B, C and D represent selected negatively stained TEM images of 6×His-
IL1-α, Ark-RUBY-IL-1α, 6XHis-D2, and Ark-RUBY-D2-FGFR1, overexpressed in E. coli 




Color of the bacterial lysate containing overexpressed Ark-RUBY-target 
protein/peptide The bacterial lysate of Ark-Ruby tagged target proteins is pale to bright 
Ruby red (Figure 5).  The RUBY red color of the bacterial lysate can be used as a reliable 
indicator of the overexpression of the Ark-RUBY tagged recombinant proteins/peptides 
and can be followed during. Data on the purification and characterization of recombinant 
IL1-α is elaborated subsequently in this study. 
 
Figure 5: showing the Ruby red color of bacterial lysate of Ark-Ruby tagged target 
protein. 
Ark-RUBY-IL-1α can be purified using Nickel-Affinity chromatography Both Ark-
RUBY-Pro and Ark-RUBY-Pep clones contain an N-terminal 6xpolyhistidine tag and so 
are amenable to nickel (Ni)-affinity chromatography using an imidazole gradient.  A 
ruby-red band formed when the bacterial lysate, containing overexpressed Ark-RUBY-
IL-1α was loaded on the Ni-sepharose column. The movement of the ruby-red band 
corresponding to Ark-RUBY-IL-1α can be followed during the purification process 
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(Figure 6, Panel A). The elution profile of Ark-RUBY-IL-1α in different imidazole 
fractions is shown in Figure 7, Panel B. 
 
Figure 6: Panel-A showing the red color of Ark-RUBY tag fused to IL-1α, on Nickel 
(Ni2+)-Sepharose column. Panel-B represents elution profile of proteins contained in 
the supernatant, obtained by using stepwise imidazole (IMD) gradient. The profile 
depicts that the protein fractions eluted at different concentrations (20mM, 50mM, 
100mM, 250mM and 500mM) of imidazole (IMD). Ark-RUBY-IL-1α is eluted at 
250mM concentration of imidazole.   
Ark-RUBY-IL-1α eluted completely in 250 mM imidazole fraction. SDS-PAGE of the 
eluted fractions revealed an intense band in the 250 mM fraction with a molecular mass 




Figure 7: Purification of Ark-RUBY-IL-1α on Nickel (Ni2+)-Sepharose column. 
Elution of proteins in the supernatant was obtained by using a stepwise imidazole 
gradient. Panel- A shows SDS-PAGE gel of protein fractions eluted at different 
concentrations of imidazole as detected by Coomassie blue. Lane 1, Pellet (P); Lane 2, 
Supernatant; Lane 3, 20mM imidazole; Lane 4, 50mM imidazole; Lane 5, 100mM 
imidazole, Lane 6, 250mM imidazole; Lane 7, 500mM imidazole; PM, Protein 
molecular weight marker. Purified Ark-RUBY-IL-1α is eluted at 250mM imidazole 
concentration with corresponding molecular weight 25kDa. Panel-B represents 
Coomassie blue stained SDS-PAGE of Ark-RUBY-IL-1α reloaded on Ni-sepharose 
affinity chromatography after thrombin treatment. Lane 1, Ark-RUBY-IL-1α (before 
thrombin treatment); Lane 2, thrombin-cleaved Ark-RUBY-IL-1α eluted at 250mM 
imidazole Concentration ( upper band corresponds to IL-1α and lower band 
corresponds to Ark-RUBY tag); After desalting 250mM imidazole fraction, the lower 
band is completely removed. Lane 3, Ark-RUBY tag is eluted at 500 mM imidazole 
concentration.  
Coomassie blue and Silver staining data revealed that Ark-RUBY-IL-1α is > 98% pure 
(Figure 8, Panel A and Panel B). It should be mentioned the 6X polyHistidine-IL-1α is 
invariably expressed in inclusion bodies. Subsequent attempts to recover 6x polyHis-
IL1α from the urea-denatured inclusion bodies was futile and did not yield any detectable 
amounts of the recombinant fusion protein. These results suggest that the Ark-RUBY tag 
not only thwarts the overexpression of the target protein(s) as inclusion bodies but also is 
amenable as an efficient purification method using Ni-affinity chromatography.  











Figure 8: Panels- A and B represent Coomassie blue and silver stained SDS-PAGE of 
Ark-RUBY-IL-1α and thrombin-cleaved Ark-RUBY- IL-1α. Panel-C  represents 
western blot of Ark-RUBY-IL-1α and thrombin-cleaved Ark-RUBY- IL-1α. Lane PM 
is the protein molecular weight marker. Coomassie blue staining, silver staining and 
western blot show a band (Mw ~17kDa) corresponds to pure IL-1α after thrombin 
cleavage. 
Ark-RUBY tag can be successfully separated from the target recombinant 
protein/peptide Ark-RUBY-IL-1α has a -LVPRGS-thrombin cleavage site. Therefore, 
purified, Ark-RUBY-IL-1α was treated with thrombin at 37 °C.  An additional 
chromatographic step of the thrombin cleaved products on Ni-sepharose showed that 
recombinant IL-1α elutes as expected in the 250 mM imidazole fraction with a small 
amount of Ark-RUBY tag but this band is completely eliminated during desalting and 
concentration of the 250 mM fraction by ultrafiltration using a 10 kDa cut-off membrane. 
The Ark-RUBY tag, due to the presence of the 6X poly-Histidine tag, is bound to the Ni-
sepharose column and is subsequently eluted at 500 mM (Figure 7, Panel A).  Coomassie 
blue staining, silver staining and Western blot of the 250 mM imidazole fraction shows a 
pure band corresponding to recombinant IL-1α (Figure 8, Panel B and Panel C). The final 
yield of pure recombinant IL-1α is 12 mg per liter of the bacterial culture. These results 
A B C
 50 
clearly show that the linker between Ark-RUBY and the recombinant target protein (IL1-
α) can be successfully cleaved and IL1-α can be subsequently purified by Ni-sepharose 
chromatography.   
Ark-RUBY tag can be successfully used for the elimination of significant 
contaminants remaining after employing Nickel-Affinity chromatography for 
purification of heat stable proteins Ark-RUBY tag is a thermostable tag (Tm > 90C). 
Owing to the excellent thermostability property of the Ark-RUBY tag, it is selectively 
used for the purification of heat stable recombinant proteins. Interestingly, if some strong 
contaminants were to be observed after employing Ni-affinity chromatography, they can 
be completely eliminated by thermal treatment. For example, the Ark-RUBY-D2 clone 
contains a N-terminal 6X poly-histidine tag and when subjected to purification using 
nickel (Ni)-affinity chromatography using a stepwise imidazole gradient showed an 
intense band in the 250 mM fraction (whose molecular mass (21 kDa) matched with that 
of Ark-RUBY-D2) along with some strong lower and higher molecular weight 
contaminant bands (Figure 9, Panel A). Those bands were completely eliminated by 
thermal treatment of the 250 mM fraction to 65°C. Coomassie blue staining revealed that 
Ark-RUBY-D2 showed that the fusion protein is > 98% pure (Figure 9. Panel B). These 
results suggest that Ark-RUBY tag can also be successfully used for the cost-effective 
production of heat stable recombinant proteins. 
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Figure 9: Purification of Ark-RUBY-D2 on Nickel-Sepharose column. Panel- A 
represents Coomassie blue stained SDS-PAGE gel of the protein fractions, eluted at 
different concentrations of imidazole. Lane 1, Pellet; Lane 2, Cell culture supernatant; 
Lane 3, 20mM imidazole; Lane 4, 50mM imidazole; Lane 5, 100mM imidazole; Lane 
6, 250mM imidazole; Lane 7, 500 mM imidazole; PM, protein molecular weight 
marker. SDS-PAGE showed that 250mM imidazole fraction contains band for Ark-
RUBY- D2 with contaminant bands and molecular weight of Ark-RUBY- D2 matches 
with ~21kDa. Panel-B represents Coomassie blue stained SDS-PAGE of 250mM 
imidazole fraction after heat treatment at 65 °C for 20 min. Lane 1, 250 mM imidazole 
fraction before heat treatment, Lane 2, pure Ark-RUBY-D2 (Mw ~21kDa) after heat 
treatment of 250mM imidazole fraction at 65 °C for 20 min; PM, protein molecular 
weight marker.  
Ark-RUBY tag can be used for the purification of peptides in a single step without 
the use of sophisticated column chromatography techniques Ark-RUBY-FGF peptide 
and Ark-RUBY-Antifungal peptide (Ark-RUBY-AF) can be purified without the use of 
multiple purification steps. Purification of the Ark-RUBY-Antifungal peptide is 
elaborately described in this section. The E. coli bacterial lysate, obtained from 1 Liter of 
culture, was systematically heated in a water bath from 25 °C to 90 °C (at 5 °C intervals) 
and the precipitate obtained at each temperature was removed by centrifugation. Analysis 
of the supernatant by SDS-PAGE revealed that only Ark-RUBY-Antifungal peptide 
remained in solution (in the supernatant) as a pure single band at and beyond 75°C 
(Figure 10, Panel A).  The presence of Ark-RUBY-Antifungal peptide is determined from 







the ruby-red color of the supernatant. Coomassie blue staining of the supernatant fraction, 
obtained from 75°C-90°C, showed that the peptide is pure.  These results suggest that 
Ark-RUBY-heat stable target peptides can be purified in single-step without the use of 
expensive chromatography techniques. This simple heat-induced purification is very 
applicable to recombinant peptides because peptides, which are mostly either 
unstructured or have simple higher order structure(s), are known to undergo reversible 
thermal unfolding. 
 
Figure 10: Purification of Ark-RUBY-AF by heat treatment without the use of column 
chromatography techniques. Panel-A represents Coomassie blue stained SDS-PAGE of 
E. coli bacterial lysate (supernatant) after heating from 25 °C to 90 °C. Coomassie blue 
staining showed that Ark-RUBY-AF remained in the supernatant as pure single band 
(Mw~12kDa) at and beyond 75 C. PM is the protein molecular weight marker. Panel-
B represents precipitated component (pellet) after heat treatment of E. coli lysate from 
25 °C to 90 °C.  
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Recombinant IL-1α is in the native conformation Far UV-circular dichroism is a 
popular biophysical technique that is commonly used for the determination of the 
secondary structure of proteins.  Far UV-CD spectrum of pure Ark-RUBY-IL-1α is 
characteristic of a helical conformation with a double minimum at 208 nm and 222 nm 
(Figure 10, Panel A). Upon separation of Ark-RUBY, pure recombinant IL1α shows a 
negative peak at 208 nm and a prominent positive peak in the range of 225 nm-230 nm, 
which is reminiscent of the native beta-barrel fold of IL-1α (Figure 11, Panel B).  
  
Figure 11: Panels- A and B represent far-UV CD spectrum of Ark-RUBY-IL-1α and 
IL-1α in 10mM PBS at pH-7.2 respectively. 
Ark-RUBY-Tag is Thermostable tag Thermal denaturation of pure recombinant Ark-
RUBY, Ark-RUBY-IL-1α, and IL-1α was monitored by Far UV-circular dichroism based 
on ellipticity changes at 228 nm.  Ark-RUBY-tag showed high thermal stability since the 
secondary structure of the tag did not change at both temperatures at 25°C and 90°C. 
Even though at both temperatures the Ark-RUBY- IL-1α showed similar secondary 
structure, the intensity at 90°C compared to the intensity at 25°C was low (Figure 12). 
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purified recombinant IL-1α is a well-folded and stable protein when it is attached to the 
thermal stable tag.  
   
Figure 12: Represents the circular dichroism of Ark-RUBY-tag, Ark-RUBY-IL-1α, and 
IL-1α, and at 25°C & 90°C. The changes of the secondary structure monitored by 
recording the shifting of the positive peak at 228 nm and negative peak at 205nm for 
IL-1α. However, for both Ark-RUBY-IL1α and Ark-RUBY tag, the secondary 
structural changes were monitored by recording the shifting of the negative peak at 208 
and 222 nm.   
Interleukin 1 alpha that is expressed fused with the Ark-RUBY-tag is biologically 
active The biological activity was assessed to ensure that the purified recombinant IL-1 
is in the biologically active conformation. IL-1α has a strong effect on splenocytes that 
are derived from C57BL/6Jmice. IL-1α is known to stimulate the secretion of IFN-γ from 
splenocytes51. Therefore, the secretion of IFN-γ was used as a measure of bioactivity of 
IL-1. Splenocytes were plated on a 96-well plate in the presence and absence of IL-1α 
(0-50 ng/mL). The secreted IFN-γ activity in the supernatant was measured after 24 hours 
by using enzyme-linked immunosorbent assay (ELISA). The concentration of IFN-γ was 
found to increase significantly upon exposure to 0.0032 to 50 ng/mL of IL-1α (Figure 
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Figure 13: Represents the production of IFN-γ by splenocytes upon addition of IL-1α 




Overexpression and purification of IL-1α in large quantities has been a challenge for 
performing detailed biophysical studies. IL-1α is very unstable, which leads to the 
degradation of the protein. Expressing IL-1α in a heterologous host such as E. coli was 
challenging. Herein, for the first time, recombinant IL-1α was produced in E. coli cells 
attached to rubredoxin using a simple IMAC SepharoseTM affinity chromatography. One 
of the most popular methods to purify recombinant proteins from a wide range of 
expression hosts is affinity chromatography.  The method relies on the incorporation of 
selective protein or peptide affinity tags which are aligned in sequence to the target 
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allowed for the acquisition of homogeneously pure IL-1α in order to perform various 
biophysical.  
Rubredoxin (Rd) from Pyrococcus furiosus has unique and interesting properties 
which can be profitability exploited as an excellent recombinant protein purification tag. 
It exhibits a bright red color due to oxidation of the central iron atom in the iron-sulfur 
core. The red color of Rd will help to track the Rd-fused target recombinant protein 
during purification as it was shown in Ark-RUBY- IL-1α.  The smaller molecular mass of 
Rd will reduce the possibility of its interference with the folding of the target protein. Rd 
proteins have an exceptionally high thermal stability (Tm > 90°C).  The extraordinary 
thermal stability of Rd can likely be used to rapidly eliminate contaminating proteins 
from the expression host by heating the bacterial cell lysate. This aspect can be expected 
to significantly shorten the time duration required for the purification of Rd-fused 
recombinant proteins/peptides.  Rd is known to be highly soluble protein. The high 
aqueous solubility of Rd can potentially facilitate the overexpression of the Rd-fused 
recombinant protein/peptide in their soluble form by preventing the formation of 
unproductive inclusion bodies. The advantage of using CNBr is that it eliminates the 
requirement of using expensive restriction proteases for separating the 
affinity/purification tag from the recombinant target protein.  Another positive feature of 
the CNBr-induced cleavage of methionine-less Rd-fused target protein(s) is that it does 
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Most secreted proteins have a hydrophobic cleavable signal peptide in their primary 
structure which guides their translocation into the lumen of the endoplasmic reticulum (ER).  
After vesicular transport through the ER-Golgi, secreted proteins are released into the 
extracellular compartment. This route of protein export is known as the classical secretion 
pathway. However, many extracellular proteins have shown to be secreted through ER-Golgi-
independent (non-classical) pathways. A common feature of non-classically secreted proteins is 
the absence of a signal peptide. The prototype member of the interleukin 1 family, interleukin 1 
alpha (IL1) is a signal-less protein that is secreted via the non-classical secretory route. IL1α 
is a multifunctional pro-inflammatory cytokine. It is a key mediator in the cytokine network, 
regulating crucial functions in the immune response, inflammation, tissue remodeling, cell 
differentiation, and cell death. This study indicated that copper (Cu++) binds to IL1α with high 
affinity and induced the formation of an IL1α dimer via the formation of an intermolecular 
disulfide bond. Also, the dimer formation did not alter the backbone conformation of the 
protein, although it displayed decreased bioactivity. Also, the dimer form as well as the 
monomer form of IL1α both exhibit high affinity to S100A13. The Cu2+ binding sites in IL1α 
were mapped by 2D HSQC spectroscopy. The HSQC data showed that many amino acids 








In living systems, many metals play crucial roles in cellular processes including 
inflammation, cells differentiation, anti-oxidant activities, and blood homeostasis1, 2. 
Calcium, zinc, copper and iron are co-factors which are involved in the activation of 
several biological reactions3, 4. Some of them have harmful effects on cells, but these 
metals are important for vital functions. Copper is involved in different biological 
processes including the production of neurotransmitters, connective tissue remodeling, 
anti-free radical reactions, and pigment development5, 6. Recent studies have 
demonstrated that copper acts as angiogenic molecules by regulating the secretion of 
FGF1 and IL-1α7. Also, some clinical data have suggested that using copper chelators 
helps in minimizing cancer progression7-9. Copper ions can have damaging effects on 
cells because it can easily exchange electrons leading to interference with cellular 
respiration, neuronal differentiation, and signal transmission. Many protein chaperons are 
involved in regulation of intracellular and extracellular copper trafficking10. In 
intracellular compartments, many proteins are known to bind to copper and serve as 
copper chaperons such as Atox1, CCS and Cox17, but still the mechanism of delivering 
copper for cellular processes is not clear11. In unconventional protein secretion of FGF1, 
copper plays an important role by binding to S10A13 and dimerizing FGF-1 by oxidizing 
cys3012. Copper induced FGF1 dimerization is crucial for non-classical protein 
secretion13, 14. Interestingly, IL-1α lacks the N-terminal signal peptide that mediates the 
secretion through the Endoplasmic-Golgi apparatus system (ER-Golgi system)15, 16. The 
ER-Golgi system is the route for moving proteins out the cells. The ER-Golgi 
transformation system needs a signal peptide that directs proteins to their final 
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destination17. IL-1α is secreted by unconventional protein secretion (UPS) into an 
extracellular compartment to exert its actions by binding to IL-1R118, 19. UPS is induced 
but not exclusively by cellular stress such as inflammation, starvation, autoimmune 
diseases and ER stress. Even though many proteins like FGF1, FGF2, IL-1β, and calcium 
binding protein S100A13 are released by UPS, the mechanism(s) that triggers the release 
of signal peptide-less proteins is still not understood20-22. Many studies have shown that 
copper (Cu2+) is involved in unconventional protein secretion of many proteins such as 
FGF1 in response to heat shock and hypoxia23-25. Also, using copper chelating agents for 
example, tetrathiomolybdate, decreases the release of FGF1 that helps in the suppression 
of tumor growth 26. Many studies have confirmed that FGF1 and IL-1α share structural 
homology as well as being released by the UPS route27, 28. Surprisingly, S100A13, an 
important component of stressreleased FGF1, is also mandatory for unconventional 
protein secretion of IL-1α29. Also, S100A13 is known to bind to Cu2+ as well as 
calcium30, 31. It is believed that Cu2+ may be involved in unconventional protein secretion 
of IL-1α. Thus, it is important to define and understand the mechanism that underlies the 
export of IL-1α by unconventional protein secretion since it medically assists in the 
management of inflammatory and carcinogenic disorders that are caused by IL-1α. The 
results of this study revealed that IL-1α has high binding affinity for copper. Copper 
induced IL-1α dimerization is mediated by the oxidation of the lone Cys143. The dimeric 
form of IL-1α shows similar properties as the monomer but exhibits lower activity.  
 Materials and Methods  
Materials VWR Scientific Inc, USA was the provider for all buffer components 
including Na2HPO4, NaH2PO4, NaCl. Lysogeny broth (LB) was purchased from EMD 
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Millipore, USA. Competent cells (DH5α and BL-21p-LysS (DE3)) were obtained from 
Novagen Inc., USA. DNA plasmid isolation kits were bought from Qiagen, USA and 
Quikchange II XL mutagenesis kits were purchased from Agilent. Nickel sepharose was 
acquired from GE Healthcare, USA. 
Expression and Purification of Recombinant S100A13  
For expression of S100A13, BL-21 Star (DE3) cells transformed with the 
expression vector pGEX-GST-S100A13 were grown at 37⁰C in one liter of culture of 
Luria broth containing 100 μg/ml Ampicillin. The protein expression was induced with 1 
mM isopropyl β-thiogalactoside for four hours after the optical density at Abs600 nm 
reached 0.4-0.6. Then, cells were harvested by centrifugation at 8000 rpm for 25 minutes, 
the pellet was suspended in 30 mls 10 mM phosphate buffer PH 7.2 and sonicated. GST-
S100A13 was bound to glutathione Sepharose that was then washed successively with 10 
mM phosphate buffer PH 7.2. Overnight cleavage on column was setup at room 
temperature on a rocker with thrombin protease for 16 hours. The cleavage product was 
washed with 10 mM phosphate buffer PH 7.2 to collect the cleavage product (S100A13). 
The GST tag was eluted using 10 mM L-Glutathione. The expression of GST-S100A13 
and the cleavage product of S100A13 were checked by SDS-PAGE stained with 
Coomassie blue. 
Far-UV Circular Dichroism Spectroscopy  
Far-UV CD measurements were accomplished using Jasco 1500 
spectropolarimeter at 25οC, and a protein concentration of 0.5 mg/mL in 10mM 
phosphate buffer (pH 7.2) using 0.1 mm bath length. All data were smoothed using the 
Savitzky-Golay algorithm.  
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Limited Trypsin Digestion (LTD)  
LTD experiments were done by incubating protein samples with enzyme at pH 
7.2 in 10 mM phosphate buffer at 37°C. The samples were collected after each ten 
minutes and the reactions were stopped immediately by adding 10% trichloroacetic acid. 
By running the samples on 15% SDS-PAGE, the results were analyzed by measuring the 
intensity of the digested protein by trypsin bands at different points of time using 
densitometric scan [UN-SCAN IT (Silk Scientific Inc., USA)].  Then the calculated 
values of bands intensities were compared with the zero-time Coomassie blue stained 
protein band.      
Isothermal titration calorimetry (ITC)  
ITC (iTC-200, Malvern Inc.) was used to determine the IL-1α (monomer or dimer 
form)-S100A13 and IL-1α-CuCl2, and different metals binding affinity. By titrating the 
ligand (loaded in the syringe) into protein solution in the reaction cell, heat changes were 
measured. All protein and metals samples were prepared in solution containing 10 mM 
HEPES buffer (pH 7.2) then all samples were degassed prior to titration. ITC experiment 
parameters performed were 30 titration injections, at 25°C with a stirring speed of 750 
rpm. ITC binding curves were best fits using one set of binding models followed by 
appropriate corrections to eliminate the heats that were generated from the dilution.   
Extrinsic Fluorescence Spectroscopy  
Extrinsic fluorescence experiments (ANS binding assays) were performed using a 
Hitachi F-2500 fluorescence spectrophotometer at 25°C. A protein concentration of 0.5 
mg/mL in 10 mM phosphate buffer, pH 7.2 was used in all fluorescence experiments. All 
fluorescence measurements were recorded using the slit width set to 2.5 nm, excitation 
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wavelength of 280 nm, and emission wavelength range from 300-450 nm. Performing 
ANS binding assays, the titrations were carried out by adding 1μL of ANS. The relative 
fluorescence intensity records were made at 510 nm.  
Equilibrium unfolding of Proteins  
Far-UV Circular dichroism (Jasco-1500) was used to study thermal and chemical 
denaturation experiments. In thermal unfolding studies, the protein concentration of the 
samples was 0.5 mg/ml in 10 mM phosphate buffer, pH 7.2. Spectra were collected from 
25°C to 90°C at five-degree intervals. To calculate Tm value where 50% of protein 
population is in the unfolded state(s), a plot was generated from fraction unfolded protein 
population versus temperature. The Cm where 50% of protein population was in unfolded 
state(s) was calculated by plotting each spectrum verses urea concentrations. Urea-
induced equilibrium unfolding of protein samples was analyzed using the fluorescence 
mode of Jasco-1500 spectrometry. Protein concentration of the sample was 0.5 mg/ml in 
10 mM phosphate buffer at pH 7.2.  
Nuclear Magnetic Spectroscopy  
1H-15N heteronuclear signal quantum coherence (HSQC) were performed on 
Bruker 700 MHz NMR, at 25°C. The protein concentration was 350 μM in 10 mM 
phosphate buffer (pH 7.2). M9 media was used to grow the bacterial hosts of IL-1α in 
which the nitrogen source was isotopes 15NH4Cl. Sparky 3.114 software was used to 
analyze 2D NMR data of labeled IL-1α.   
Bioactivity assay  
HEK-BlueTM IL-1α/IL-1β cells (Invivogen) allow monitoring the bioactivity of 
IL-1α and IL-1β by activation of the NF-kB and AP-1 pathways. The response to TNF- α 
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is blocked, so the cells are responsive only to IL-1. The binding of IL-1 to cell surface 
receptors triggers specifically the NF-kB cascade leading to producing the secreted 
embryonic alkaline phosphatase (SEAP). A 96-well plate was seeded with 50,000 
cells/well of HEK-BlueTM IL-1α/IL-1β cells, then the cells were treated with media 
containing 0.4 to 10 ng/ml IL-1α or copper induced IL-1α dimerization. Supernatant 
SEAP concentrations were detected by quantifying Quanti-BlueTM (Invivogen) via 
reading the wells at 650 nm.  
  Results and discussion  
Copper dimerizes Interleukin-1 alpha 
In order to examine the effects of copper on IL-1α, CuCl2 was incubated with IL-
1α at room temperature. One migrating band resolved when IL-1α in the absence of 
copper was run and two bands of IL-1α-copper complex were migrated through non-
reduced SDS-PAGE representing the monomer and the dimer (Figure 1). In contrast to 
the monomer, double bands appeared when the same concentration of IL-1α was treated 
with 30 μM CuCl2. For calculating the copper concentration that induces complete 
protein dimerization, IL-1α was treated with different concentrations of CuCl2. Then, IL-
1α was electrophoresed in non-reduced SDS-PAGE. Dimer band of IL-1α appeared even 
at a low concentration of CuCl2. The intensity of dimer bands increased while the 
concentration of CuCl2 increased. Compete dimer band displayed with no monomer band 









Figure 1: illustrates Non-reduced SDS-PAGE that revealed the dimer formation of IL-1α 
after treating it with CuCl2. Uncompleted dimerization of IL-1α under influence of 
particular concentration of CuCl2 indicates that some proteins were at monomer form.    
Figure 2: demostrates the dimer formation and monomer reduction of IL-1α while CuCl2 
concentrations are increasing. The concentrations of CuCl2 in (μM) are shown above each 
band. A: The dimer form of IL-1α appeared at a low concentration of CuCl2. C: Both 
monomer and dimer form of IL-1α appeared on the non-reduced SDS-PAGE. C: The 
maximum concentration of CuCl2 for complete dimerization is 46 μM CuCl2. D: the 
densitometric scan of the SDS-PAGE gel that shows the dimer formation versus the 
monomer form of IL-1α in presence of different concentrations of CuCl2.  




These results indicated that specific disulfide bands were formed between two 
cysteine amino acids of different monomers of IL-1α. We propose that forming the dimer 
form of IL-1α is relatively important for some biological activities. It may explain that 
the IL-1α might be released at high volume to reach maximum effects.  
Secondary structure of IL-1alpha does not alter upon copper-induced dimerization  
The secondary structure of IL-1α belongs to β-trefoil family that is one of the ten 
of protein super families32. Several proteins types that are included in this family such as 
FGF-1, FGF-2, IL-1β, and soybean trypsin inhibitors33. IL-1α consists of twelve β 
strands that are arranged into trefoil units called hairpin. The twelve β-strands are folded 
into three similar trefoil units of β-β-β-loop-β32. Circular dichroism is a valuable 
technique for examining the secondary structure changes induced in protein-protein 
interaction. CD spectra of the dimer form of IL-1α gets overlaid well (Figure 3) 
Figure 3: Far-UV spectra of the monomer form of IL-1 α (orange dots) and the dimer 
form of IL-1 α (blue dots). 
with the monomer type, displaying the quality feature of the positive ellipticity shoulder 
in the wavelength range 220-240 nm, and a negative shoulder in the region of 200-210 
nm. These spectral characters indicate that the native β-trefoil conformation is not 
significantly disturbed because of the dimer formation.  
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No conformational changes in three-dimensional structure upon copper induced 
dimerization of IL-1α monitored by (ANS) binding assay 
  The tertiary structural changes of proteins were examined by using the ANS 
binding assay. ANS is hydrophobic, non-polar dye that has been used to study proteins 
conformational changes. Polar amino acids make hydrogen bonds with water whereas 
non-polar and aromatic amino acids are hydrophobic and are usually buried inside the 
core of the protein(s)34. Upon protein-protein interaction, hydrogen bonds are formed 
between two reactants that cause conformational changes. Monitoring ANS binding, 
conformational changes can be analyzed. The extrinsic fluorescent probe of ANS binds to 
solvent accessible hydrophobic surface(s) in the proteins35. In this context, measuring the 
changes of ANS fluorescence helps to study structural differences between the monomer 
and the dimer form of IL-1α (Figure 4).  
Figure 4: ANS binding curve of the monomer form of IL-1 α & the dimer form of IL-1 α 
Typically, hydrophobic portion(s) of proteins are buried in the protein core, so 
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are present. The emission intensity of ANS binding to the dimer form of IL-1α is higher 
than the monomer form when it binds to ANS. This indicates that induced dimerization 
encourages a modest conformational change causing an increase in the solvent-exposure 
of the hydrophobic surfaces(s).  
No conformational changes upon copper induced IL-1α dimerization detected by 
Limited Trypsin Digestion (LTD) 
Trypsin is a serine protease that cleaves at the carboxyl terminal end of lysine and 
arginine residues. Many factors affect the rate of the protease-substrate cleavage reaction 
including number of hydrogen bonds between the cleavage sites, the degree of protease 
accessible to the cleavage site, degree of protein folding, and flexibility of the substrate36. 
In this context, the LTD assay is a useful technique to study protein flexibility and 
possible structural changes in the protein backbone caused by protein dimerization.  LTD 
was performed on the monomer and the dimer form of IL-1α to determine any 
conformational and flexibility changes of the dimer form compared to the monomer 
form. The progress of the cleavage reaction of the substrates was determined by 
comparing the measurements of the intensity of the zero trypsin, non-cleaved band at 19 
kDa (monomer) and 38 kDa (dimer) Coomassie blue stained bands on SDS-PAGE with 
trypsin-substrates bands at different time periods.  Based on the digestion rate of the 
monomer and the dimer form of IL-1α, both showed higher susceptibility to trypsin 
(Figure 5). The monomer form of IL-1α began cleavage by trypsin after five minutes of 
incubation until fifty percent of Cu2+ free IL-1α was cleaved after 30 minutes from the 
initiation time. Copper induced IL-1α dimerization showed better stability than the 
monomer form. The dimer was stable till twenty minutes of incubation then cleavage 
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started gradually after 30 minutes until fifty percent of the dimer became cleaved after 50 
minutes.  
Figure 5: Densitometric analysis of the SDS-PAGE gel analyzing the flexibility of the 
monomer and the dimer form of IL-1α.   
The monomer form of IL-1α showed higher vulnerability to trypsin than the dimer form 
which suggests that the dimer form is more tightly packed. These results indicate that the 
dimer formation of IL-1α has better stability effects on the flexibility of the backbone.   
Copper induced IL-1α dimerization alters the stability of the protein 
Metal binding induces conformational changes that alter the stability of the protein. It is 
important to investigate the properties of metal binding effects in order to understand the 
physiological role(s) that are changing the functional characteristics of the proteins. In 
this context, thermal denaturation was performed to analyze the effects of copper on 
thermodynamic stability of protein dimerization. Far UV CD spectroscopy was used to 
measure the thermal stability of the monomer and the dimer forms of IL-1α. The thermal 
denaturation of the monomer form of IL-1α was examined by analyzing the fraction 
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Figure 6: shows thermal stability of IL-1α forms (monomer and dimer). 
The monomer form of IL-1α began unfolding at temperature 50°C and it was 
completely unfolded at 90°C. In order to analyze the denaturation temperature, the 
melting point (Tm) value should be determined. Tm is the temperature at where 50% of 
the protein population exists in the denatured state. The Tm value of the IL-1α in 
monomer states is at 60°C. Interestingly, the copper induced IL-1α dimerization form 
shows remarkable thermal stability. The thermal stability of the dimer form increases to 
which the protein starts unfolding at 60°C. The melting point of the dimer form is 70°C. 
The results suggest that the compact protein structure of the dimer form improved leading 
to increase the stability of the protein. Also, the formation of disulfide bonds helps in 
increasing the stability of the dimer form of IL-1α.  
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Copper induced IL-1α dimerization increases protein chemical stability  
In order to complete the protein stability investigation, chemical denaturation was 
monitored to study the influence of metal binding on protein conformation. It is known 
that metals alter the mass of hydrogen bonds across the protein core. The Chemical 
stability was also measured using Far UV CD spectroscopy for the monomer and the 
dimer forms of IL-1α. The metal binding conformational changes were analyzed by 
measuring the fractions unfolded for both IL-1α forms to calculate chemical denaturant 
melting point (Cm). Cm is the concentrations at which 50% of the proteins are in 
denatured state. Urea was used to study the effect of metal binding on the chemical 
stability of proteins (Figure 7).  
Figure 7: displays the chemical stability of IL-1α in two forms (monomer and dimer). 
Urea is known as a non-ionic denaturant salt which breaks hydrogen bonds. The 
unfolding state of the monomer form of IL-1α began at a urea concentration of 2.18 M 
and the protein was completely unfolded at a urea concentration of 4.29 M. The Cm 
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value of the monomer form was 3.5 M. Interestingly, the copper induced IL-1α 
dimerization showed that the unfolded state started at a concentration of 3.5 M urea and it 
was entirely unfolded at 4.85 M. The Cm value of the dimer form was 4.5 M. This result 
indicates that copper binding to the protein stabilizes the protein by increasing the 
hydrogen bonds and decreasing the protein surface exposed to the solvent.  
Cysteine 143 mediates disulfide-liked dimerization of IL-1α  
FGF1 is released from NIH 3T3 cells as a biologically inactive homodimeric form 
in response to heat shock. During heat shock, the cysteine residues of FGF1 are important 
in the non-classical secretion mechanism since FGF1 free cysteine residues are not 
released in response to stress37. Also, in non-classical secretion of peroxiredoxine 1 and 2 
that do not have signal peptides, cysteine residues mediate the protein dimerization in the 
cytoplasm and during the protein translocation outside of the cells38. To gain further 
insight into understanding the non-classical protein secretion of IL-1α, and since IL-1α 
has only one cysteine; we attempted to determine whether or not Cys143 is essential in 
protein dimerization. The cysteine residue was mutated to serine, as both amino acids are 
similar except the sulfur thiol atom in cysteine is replaced with oxygen in serine. The 
single IL-1α C143S mutant was overexpressed using the same conditions that were 
applied in producing the wild type of IL-1α. The IL-1α C143S mutant was successfully 
overexpressed and the secondary structure of the mutant IL-1α matched that of the wild 
type. Treating the mutant IL-1α with CuCl2 did induce IL-1α dimerization. The results 
suggested that cysteine oxidation mediates the formation of a disulfide linked dimer of 
the wild type IL-1α whereas IL-1α free cysteine failed to present the dimer form. 
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Figure 9: SDS-PAGE showed A: the wild and the mutant proteins have the same 
molecular weight. B: The secondary structure of the mutant overlays on the wild type of 
IL-1α. C: Copper induced wild type of IL-1α whereas the copper did not dimerize the 
mutant.       
Interleukin 1 alpha is a copper binding protein as monitored by isothermal titration 
calorimetry (ITC)  
In this study, ITC was used to examine the affinity of IL-1α not only to CuCl2 but 
also to different metals such as CaCl2, FeCl2, NiCl2, CuCl, MnCl2, ZnCl2, CoCl2, CdCl2 
and MgCl2 (Figure 10). ITC revealed that the type of interaction of IL-1α and CuCl2 is 
exothermic and the reaction has negative enthalpy. The binding curve of the IL-1α and 
CuCl2 is hyperbolic. The binding constant (Kd) was calculated after applying a best-fit 
model. The Kd value of the IL-1α to CuCl2 was 1.9 μM. ITC results demonstrate that 
copper interacts with IL-1α at high affinity which causes conformational changes. These 
data are in good agreement with copper induced IL-1α dimerization, and protein stability 
experiments as well as ANS binding assays and trypsin digestion. To determine the 
specificity of copper binding, ITC was used to titrate IL-1α with various metals. Some 
metals like MgCl2, NiCl2, CdCl2, and FeCl2 showed weak binding, but the binding did 
not induce IL-1α dimerization. This means the reaction of these metals with IL-1α were 











Figure 10: Illustration of the ITC data of IL-1α titrated with different metals. A: Copper 
shows strong binding affinity to IL-1α. B, C, D, E, F, G, H, and I: illustrate IL-1α has no 
binding affinity to NiCl2, MgCl2, CdCl2, CoCl2, FeCl2, MnCl2, ZnCl2, and CaCl2.   The 
upper panels of each data represent the raw data and the bottom panels are the best fits of 
the raw data. The protein concentration was made of 100 μM in 10 mM phosphate buffer 
at PH 7.2. All ligands concentrations were made of 500 μM.      
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In order to examine the dimerization effects of all tested metals, SDS-PAGE of interleukin 
1 alpha incubated with different metals revealed that only the cupric form of copper had 
the dimerization effect in interleukin 1 alpha (Figure11).  
Figure 11 shows the dimerization effect of copper(II) comparing to different metals. 
Monomer and dimer forms of IL-1α are S100A13 binding proteins 
Studying protein-protein interactions is critical to elucidate the mechanism of IL-
1α export. The S100A13 protein is an important partner for signal-less proteins export by 
the non-classical pathway. The unconventional secretion of FGF1 involves multiprotein 
complex formation including FGF1, S100A13, and C2A of synaptotagmin 1(Syt1)29. 
S100A13 is a member of the S100 proteins family which play key roles in cellular 
functions with some indication of participating in tumor progression39. S100A13 is 
calcium-binding protein because of the presence of the EF-hand domains40. Due to the 
absence of a signal peptide, S100A13 is exported by a non-classical mechanism41. ITC 
has shown that the IL-1α (monomer) is binding to S100A13 with a high affinity, so that 
in this study, ITC is used to determine whether or not the copper induced IL-1α dimeric 
form binds to S100A13. The data illustrates that the dimeric form of IL-1α has high 
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binding affinity to S100A13 which suggests that the dimer formation is important for the 
non-classical protein secretion of IL-1α. Also, the conformational change upon copper 
binding that was monitored by the ANS binding assay does not alter the binding site 
where S100A13 interacts.  
Figure 11: A) ITC of the monomer form of IL-1α versus S100A13. B) ITC of copper 
induced IL-1α dimerization versus S100A13. S100A13 shows strong binding affinity to 
the dimer form of IL-1α in both conditions. The upper panels of each data represent the 
raw data and the bottom panels are the best fits of the raw data. The protein concentration 
was made of 100 μM versus 500 μM of S100A13 in 10 mM phosphate buffer at pH 7.2. 
The type of interaction of copper induced IL-1α dimerization and S100A13 and 
the monomer form of IL-1α that was titrated with S100A13 was exothermic with 
negative enthalpy. The binding curve for both was hyperbolic. The binding constant (Kd) 
was calculated after applying the best-fit model. The Kd value of monomer form of IL-1α 
to S100A13 was 1.3 μM. Interestingly, the Kd of binding was 1.34 μM for copper 
induced IL-1α dimerization. 
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Copper induces several chemical shifts    
Monitoring backbone conformational changes of proteins can be done using 1H-15N 
heteronuclear single quantum coherence (HSQC) spectroscopy42. Studying 1H-15N 
crosspeaks, the microenvironment of the amino acids can be examined upon addition of 
metals or any ligand by analyzing the chemical shift perturbation43. Due to the fact that 
Cu++ is paramagnetic, the resonances of the amino acid residues were beyond the 
detection limit upon binding to Cu++44. Therefore, in this study, corpus chloride is used to 
study the backbone conformation of the protein for two reasons. Firstly, Cu(I) is 
diamagnetic, so that 1H-15N spectra are not broadened upon binding. Secondly, ITC data 
showed Cu(I) binds to IL-1α, but it does not cause dimerization (Figure 12).  
Figure 12: Panel A) Non reduced 15% SDS-PAGE that showed IL-1α without Cu(II) 
(lane number 1),  Cu(II) induced IL-1α dimerization (lane number 2), & IL-1α with Cu(I) 
with no dimerization (lane number 3)  Panel B) ITC of IL-1α titrated with Cu(I)  
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Upon treating with copper(I), the analysis of superimposition of the 1H-15N HSQC 
spectra of treated and non-treated IL-1α on the chemical shift perturbation plot showed 
that copper induces drastic crosspeak shifts corresponding to where copper is binding 
(Figure 13).  
Figure 13: Panel-A) The 1H15N HSQC of IL-1 (red) is superimposed onto IL-1α treated 
with copper (I) (blue). Panel-B) The chemical shift perturbation plot of the IL-1α treated 
with copper.
 
In addition, residues Val2, Ile10, Lys11, Lys61, and Arg8, Ser54 that are located 
in strand one undergoes drastic crosspeak shifts. Also, amino acid residues that are 
located in strand two including Ala27, Ala34, and Ala35 had
 
significant 1H-15N chemical 
shift perturbation. Strand three was also perturbed as Gly96, Phe46, and Lys69 displayed 
chemical shifts. Amino acids residues Asp45, Ser53, and Thr107 that are located in 
strand four were also perturbed. Unfortunately, cysteine was not assigned in the data of 
BMRB number 16379, so that it was not possible to calculate the chemical shift. 
However, cysteine was involved in copper induced dimerization as the study showed that 
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mIL-1α (C143S) was not induced to build a homodimeric form of IL-1α. 1H-15N data 
analysis is consistence with the ITC  data showing that IL-1α has good binding affinity to 
copper as many amino acids residues are binding to copper.  
Cooper induced IL-1α dimerization is less biologically active than the monomer
 
The level of secreted embryonic alkaline phosphatase (SEAP) produced by HEK-
blueTM was reduced when the cells were exposed to the media that contained copper 
induced IL-1α dimerization (Figure 14). At high concentration, the dimer form shows 
some activity because the media is in reduced environment that may break the disulfide 
bonds producing some monomer form of IL-1α.  
Figure 14: Represents the production of SAEP by HEK-blue cells upon addition of IL-1α 
(0-50 ng/mL). The calculated standard errors were derived from triplicate measurements. 
The monomer form of IL-1α showed significant activity as the concentrations of 
SEAP increased with the concentration of IL-1α. Also, the activity of the reduced form of 
copper induced IL-1α dimerization showed similar results as the monomeric form that 
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and protein bioactivity.  
It is known that copper has a role in non-classical protein secretion of IL1α. 
However, many questions related to the mechanism which is involved in protein export 
are still unanswered. Upon binding to copper, conformational changes have occurred to 
IL1α. Copper induces IL1α dimerization which increases protein stability that has been 
monitored by thermal and chemical stability of the protein. Increasing the compact nature 
of the protein is correlated with the results of the limited trypsin digestion which 
enhances the stability of the dimer form. In the presence and absence of copper, the dimer 
form of IL1α showed high binding affinity to S100A13 that suggests the involvement of 
copper in non-classical secretion of IL1α is mediated by inducing the dimerization. It 
looks like S100A13 is a Cu++ provider for inducing IL1α dimerization. This study should 
be extended further to investigate another partner of S100A13- IL1α (monomer and/or 
dimer) that helps to make the membrane to flip out and make the delivery such as in the 
case of annexinII.    
Conclusions 
Understanding the mechanism of non-classical protein secretion of IL1α helps in 
designing a treatment for several IL1α related pathological conditions such as cancer and 
rheumatoid arthritis. We were able to successfully demonstrate the copper induced 
dimerization of IL1α under in vitro conditions. At approximately 46 µM of CuCl2, the 
monomeric form of IL1α transforms into a dimer. We have identified the Cu2+ mediated 
mechanism of dimerization where the single cysteine at position 143 becomes oxidized 
resulting in the formation of an inter-disulfide bond leading to the generation of the 
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homodimer. Also, the result that was gained from this study found that the dimer form of 
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The interleukin-1 (IL-1) family of pro-inflammatory cytokines is known to amplify 
cancer metastasis, making them potential targets for treatment. Non-classical secretion of 
IL-1α appears to be mediated by a Cu2+ binding. Hence, development of drugs to inhibit 
the Cu2+ mediated oligomerization and resultant multiprotein complex interactions could 
block tumor angiogenesis. This study focused on elucidating the underlying molecular 
effects of non-classical release of IL-1α upon treatment with the drug amlexanox (AMX). 
AMX has low solubility below pH 8.2. This finding is characteristic of metal chelators 
such as ethylenediamine tetraacetic acid (EDTA), nitrilotriacetic acid (NTA), and 
iminodiacetic acid. Also, AMX can bind to copper as well as IL-1α that may interfere with 
the non-classical secretion of the protein. Binding of IL-1α to AMX may induce 
conformational changes, which interfere with the flexibility and stability of IL-1α. This 
study shed light in identifying the cause and plausible mechanism involved in the secretion 
of these intriguing cytokines, which could pave the way towards development of potent 










IL-1α is a key member of the IL-1 family1, 2. It is unique in certain properties 
compared to the other members of the cytokine family3, 4. IL-1α expression is 
significantly responsive to wide range of external stimuli5-7. IL-1α plays a key role in 
many cellular processes such as inflammation, proliferation, and immunological reactions 
against many microbial infections8, 9. IL-1α also plays key roles in molecular decisions 
during infections and stress conditions10, 11. Cellular reposes to IL-1α actions represents 
through the inflammatory mechanism that activates inflammatory cells12, 13. Also, many 
studies have linked IL-1α to wound healing, rheumatoid arthritis, cancer metastasis, and 
Alzheimer’s disease12, 14. IL-1α lacks the signal segment that guides protein secretion 
through the endoplasmic reticulum-Golgi apparatus complex15, 16. In non-classical 
secretion of IL-1α, multiprotein complex formation takes place that acts as a cargo 
targeting IL-1α to be exported outside the cells15, 17. The underlying mechanisms 
governing IL-1α export from cells requires further investigation. Also, the mechanism of 
multiprotein complex formation of IL-1α and S100A13 inside cells needs to be 
deciphered. S100A13 is a member of S100 protein family that binds to calcium18, 19. The 
S100 protein family is characterized by forming two EF segments that are classified into 
a C-terminal hand and an N-terminal hand20-22. S100A13, a Ca2+ binding protein, is a 
small protein that exhibits ubiquitously in different tissues such as intestine, heart, 
kidney, ovary, and muscles23-25. S100A13 regulates a wide range of cellular functions 
including cellular proliferation, muscle contraction, and protein export26-28. In fact, 
S100A13 is the only S100 member that is involved in protein translocation of signal-less 
proteins by non-classical protein secretion during cellular stress29-31. IL-1α is well known 
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as an angiogenic cytokine that secretes into the extracellular compartment under stress 
conditions without a signal peptide32, 33. Uncontrolled release of IL-1α is responsible for 
various pathological conditions such as autoimmune disorders and tumor angiogenesis8, 
34. Several reports confirmed the role of IL-1α in the growth progress of breast and 
intestinal cancer9, 35. Several studies have shown copper (Cu2+) is involved in non-
classical secretion of signal-less proteins36-38. Cu2+ plays a crucial role in forming 
multiprotein complex release of FGF139, 40. It was demonstrated that amlexanox (AMX) 
(Figure 1), the anti-allergic and anti-inflammatory drug41, can inhibit non-classical 
secretion of FGF142. The mechanism that involves the inhibition of FGF1 secretion by 
AMX includes different processes.  Some scientists confirmed that AMX binds to 
S100A13, which in return prevents multiprotein complex formation that includes FGF1 
and S100A1343, 44. Also, some studies showed that AMX is used to treat aphthous ulcers, 
inflammation of gums or tongue, because it inhibits the release of inflammatory 
mediators45, 46. Studying the role of AMX in exporting IL-1α paves the way for 
developing a new drug that inhibits the non-classical secretion of IL-1α.  
 
Figure 1: depicts the chemical structure of amlexanox47. 
      The main objective of the present study is to shed light on how AMX binds to 
IL-1α and stops non-classical secretion of the protein. This investigation includes several 
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physical experiments to elucidate the role of AMX on the monomer/dimer form of IL-1α 
and to investigate if AMX may be involved in regulating copper involvement.  
Materials and Methods  
Materials All buffer components including Na2HPO4, NaH2PO4, and NaCl were 
purchased from VWR Scientific Inc, USA. Lysogeny broth (LB) and urea were bought 
from EMD Millipore, USA. 1-anilino-8-naphthalene sulfonate and Trypsin were obtained 
from Sigma. Nickel sepharose was obtained from GE Healthcare, USA. 
Far-UV Circular Dichroism Spectroscopy Far-UV CD measurements were 
accomplished using Jasco 1500 spectrometer to determine the secondary structure 
changes. To obtain the CD spectrum, the machine was setup to scan the protein samples 
at a speed of 20 nm/min using wavelength of 190-250 nm at 25°C or at specific 
temperature when it was required.  The protein concentration of 0.5 mg/mL in 10mM 
phosphate buffer (pH 7.2) was examined. All data were smoothed using the Savitzky-
Golay algorithm for the best fit. Far-CD was used for studying the following experiments  
A: Thermal Denaturation Thermal denaturation studies were performed on the JASCO-
1500 spectrometer to reveal how temperature affects the stability of IL-1 in presence and 
absence of AMX. Spectra were collected from 25°C to 90°C in five-degree intervals.  
B: Chemical Denaturation (Urea denaturation) For the chemical denaturation studies, 
8M urea was used to induce protein denaturation. This process was monitored using 
JASCO-1500 s spectrometer. Data of samples of 0.5 mg/ml proteins in 10 mM PB were 
each over the titration of urea. Samples of 0.5 mg/ml protein in 10 mM PB were used for 
titration with urea. These experiments revealed information about the stability of the 
protein in the presence and absence of AMX.  
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Extrinsic Fluorescence experiment Extrinsic fluorescence experiments (ANS binding 
assays) were performed using a Hitachi F-2500 fluorescence spectrophotometer at 25°C 
to provide information regarding the protein’s tertiary structure. ANS (8-
anilinonaphthalene-1-sulfonic acid) is an extrinsic fluorophore that fluoresces when it 
binds to solvent exposed hydrophobic regions of a protein. A protein concentration of 0.5 
mg/mL in 10 mM phosphate buffer, pH 7.2 was used. All fluorescence measurements 
were recorded using the slit width set to 2.5 nm, excitation wavelength of 280 nm, and 
emission wavelength range from 300-450 nm. Performing ANS binding assays, the 
titrations were carried out by adding 1μL of ANS per interval. The relative fluorescence 
intensity was recorded at 510 nm.  
Limited Trypsin Digestion (LTD) Proteolytic trypsin digestion was performed to 
determine the structural flexibility of the protein with and without the ligand. Trypsin 
cleaves peptide bonds at the C-terminal end of lysine and arginine amino acids residues. 
The water bath was used to incubate the samples immediately at 37 °C. After the samples 
were removed from the water bath, TCA preparation was performed on each sample to 
stop the trypsin reaction. Samples were then assessed using 15% SDS-PAGE analyzed 
with UN-SCAN-IT gel software (Silk Scientific Inc., USA). The intensity of the bands in 
the gel stained with Coomassie blue were compared to control bands containing pure 
protein with or without the ligand.  
Isothermal titration calorimetry (ITC) Isothermal calorimetry (ITC) is a great 
thermodynamic technique used to study the binding affinity of interacting 
macromolecules, by measuring changes in entropy and enthalpy in this case, the binding 
of AMX and IL-1α. The ITC system consists of two adjacent cells (reference cell and 
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sample cell) in an adiabatic jacket, which prevents heat transfer between the environment 
and the cells. Protein samples were prepared in 10 mM phosphate buffer pH 7.2. The 
protein sample was degassed at 25⁰C before titration. During the titration, the generated 
heat from the binding of ligands to the protein was measured. Then, the data was 
processed using Origin software provided by the manufacturer to get the best fit. Kd 
value, the equilibrium dissociation constant of the reaction, was calculated for each 
ligand.  
Results and Discussion  
AMX behaves as copper chelator molecules 
Amlexanox needs high pH to be dissolved completely. It dissolves at pH 8.8, 10 
mM phosphate buffer. Dissolving at high pH is characteristics for metals chelators such 
as EDTA48. This finding may suggest that AMX can be used as copper chelators. In this 
context, ITC was performed to confirm whether or not AMX binds to copper (Figure 2).  
 
Figure 2: Isothermogram representing the binding of AMX to copper. The data 
represented the best curve fit using ITC software.   
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The calculated Kd value calculated from the ITC data was 1.6 µM. This finding 
indicates that AMX can regulate the involvements of copper in many biological 
processes.  
AMX prevents copper induced IL-1α dimerization 
The previous results may indicate that AMX could stop copper induced IL-1α 
dimerization. The homodimer of IL-1α is mediated by the oxidation of the thiol group of 
cysteine 143. In order to examine this theory, IL-1α was incubated with different 
concentrations of AMX followed by addition of 46 µM of CuCl2, the concentration 
required to induce dimerization to 100 µM of IL-1α completely. 15% SDS-PAGE was 
used to reveal the results (Figure 3 A & B). It seems that AMX prevents oxidation of 
Cys143’s thiol group by copper, so that inter-disulfide bond formation was blocked.    
 
 
Figure 3: A) AMX interferes with Cu++ induced IL-1α dimerization. The protein 
samples were first incubated with different concentrations of AMX and then CuCl2 
was added. The numbers above the gels represent the protein samples based on 
AMX concentrations:  1) IL-1α monomer, 2) 20μM AMX, 3) 25μM AMX, 4) 30μM 
AMX, 5) 35μM AMX, 6) 40μM AMX, 7) 45μM AMX. 8) 50μM AMX, 9) 55μM 
AMX, 10) 60μM AMX, 11) 65μM AMX, 12) 70μM AMX, 13) 75μM AMX, 14) 
80μM AMX, 15) 85μM AMX. 16) 90μM AMX. 17) 100μM AMX. B) 
Densitometric scan of the monomer formation of IL-1α that induce at different 
concentrations of AMX. 





















Densitometric Scan of AMX treatments of Copper induced 
IL-1α dimerization 




  AMX binds to IL-1α 
ITC was used to determine AMX binding affinity of IL-1α. The binding affinity is 
represented by the dissociation constant (Kd) value that is the reciprocal of the 
association constant (Ka) value. Ka value is obtained from ITC data. A small Kd value 
correlates to high binding affinity. The Kd value for AMX binding to IL-1α was 1.9 µM 
as shown (Figure 4). This indicates AMX has high binding affinity to the protein. These 
results may confirm that AMX might be used for inhibiting non-classical release of IL-
1α.    
 
Figure 4: Isothermogram representing the binding of AMX to IL-1α. Protein 
concentration was 100 µM and AMX was 50 µM. All samples were prepared in 
phosphate buffer.  
 
AMX decreases IL-1α affinity to copper  
Copper induced IL-1α dimerization is mediated by cysteine 143. Copper oxidizes 
the thiol group to convert cysteine to cystine. Forming a disulfide bridge between two 
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protein molecules. AMX prevents IL-1α dimerization by copper and also it chelates 
copper. AMX prevents copper-induced IL-1α dimerization by chelating copper. In order 
to confirm that AMX and copper bind in the same site, ITC was performed with IL-1α 
mixed first with AMX then titrated with copper chloride (Figure 5). ITC data showed that 
copper lost its affinity to IL-1α in presence of AMX.  
 
Figure 5: ITC data is showing the binding of copper to AMX bound IL-1α. After AMX 
binding, the bound form was dialyzed to remove all AMX that can bind to copper. All 
samples were prepared in phosphate buffer. 
 
AMX binding alters IL-1α conformation 
Anilino naphthalene 8-sulfonate (ANS) is a non-polar reagent used to examine the 
flexibility of solvent-exposed hydrophobic surfaces in proteins. Upon binding to 
hydrophobic pocket within the protein, ANS fluoresces which helps examine the 
structural rigidity of proteins. Hydrophobic interactions of proteins are important in 
protein folding and stability. Upon binding to ANS, IL-1α shows an emission maximum 
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at 510 nm and the surface exposed hydrophobic regions of protein in presence of AMX 
were saturated at ANS concentration of 150 µM (Figure 6).  Whereas the ANS saturation 
curves of IL-1α without AMX were saturated at ANS concentration 115 µM. These 
finding suggest that in presence of AMX, the protein is more structurally flexible in 
which the solvent exposed hydrophobic surfaces are reduced in presence of AMX, 
indicating that AMX helps shift the protein to a more compact state.  
 
 
Figure 6: ANS binding curve of IL-1α with and without AMX. 
 
AMX increase IL-1α flexibility  
Limited proteolytic digestion experiment investigates the mode of action between 
the protein and the ligand. In general, protein-ligand binding can mask the potential 
cleavage sites of the substrate. The masking will delay the proteolytic enzyme to reach 
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pattern between the free protein and the protein-ligand bound forms on the SDS-PAGE 
gel. In order to study the effects of AMX on the conformational flexibility of IL-1α, 
limited trypsin digestion was used. Trypsin cleaves at the carboxyl end of the amino acids 
lysine and arginine unless proline comes after either one of them. IL-1α has four arginine 
residues and eleven lysine residues and both are not followed by proline, so there are 
fifteen potential trypsin cleavage sites. In time dependent trypsin digestion, protein 
samples were incubated at 37 °C using water bath. Then, the results were revealed using 
15% SDS-PAGE gel followed by measuring the bands intensity using densitometric scan. 
With no AMX, IL-1α was more susceptible to trypsin in which trypsin cleaved 50% of 
the proteins after 25 minutes whereas IL-1α in presence of AMX got cleaved after 35 
minutes (Figure 7). It seems that binding to AMX, IL-1α has enhanced resistance to 
trypsin action. This indicates that AMX binds where trypsin cleavage sites are located. 
This decreased susceptibility to trypsin digestion suggests that the backbone of IL-1α 
mixed with AMX is more flexible than IL-1α alone.  
 
Figure 7: Densitometric plot of limited time trypsin digestion showing the rate of 
cleavage of IL-1α, incubated at 37⁰C.  The insert shows the 15% SDS-PAGE with 






















Desitometric Scan of trypsin digestion of IL-1A in presence 




IL-1α is stabilized by AMX 
Thermal denaturation of IL-1α was examined by circular dichroism from 25-90°C at 5°C 
increments. Unfolding of the proteins under different temperatures was monitored by the 
change in secondary structure of IL-1α at 208 nm and 215 nm. The temperature-induced 
unfolding curves of the IL-1α with no AMX and IL-1α with AMX show that IL-1α with 
AMX is more stable at higher temperatures than the protein alone, shown in (Figure 8). 
Denaturation midpoint (Tm) where 50% of the proteins are in the folded state was 65 °C 
in presence of AMX whereas with no AMX the Tm was 60°C. These results indicate that 









Figure 8: Thermal denaturation of IL-1α in presence of AMX (purple squares) and 
absence of AMX (red rhomboids). Far-CD was probed to examine of the protein at 




























The chemical stability of IL-1α without and with AMX was examined by urea-induced 








Figure 9: Chemical denaturation of IL-1α in presence and absence of AMX. Far-CD was 
probed to examine of the protein stability in urea.  
In presence and absence of AMX, the protein exists in the native conformation at 
zero concentration of urea. During titration with urea, the unfolded states of the protein 
molecules are monitored. The Cm values where 50% of the proteins exist in folded state 
were calculated from urea unfolding curve. The Cm value of IL-1α with AMX was 4.3 M 
urea whereas without AMX the Cm a value was 3.3 M urea. The results indicated that as 
urea is neutral denaturant that disturbs hydrogen bonds within the protein molecules, so 
in presence of AMX, urea interfered with the hydrogen binds occurred at high 
concentration. As urea is a neutral denaturant that disturbs hydrogen bonds within protein 
molecules, these results indicate that in the presence of AMX urea interferes with the 
hydrogen bonds at high concentrations. These results of protein stability are consistent 
with the findings of limited trypsin digestion and ANS binding assay that showed 
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Conclusions 
The non-classical secretion of signal-less protein involves protein cargo that is 
made from multiprotein complex. The non-classical secretion of signal-less proteins 
involves a multiprotein complex for transport. In the case of IL-1α, S100A13 is involved 
in protein export in presence of copper. The results of this study showed that AMX can 
bind to IL-1α and also chelates copper. AMX binds to cysteine 143 of IL-1α where 
copper can bind and form a homodimer of IL-1α. Therefore, AMX can mask the thiol 
group and protect it from copper oxidation. Upon binding to AMX, IL-1α showed some 
conformational changes that stabilized the protein in some ways. For future work, NMR 
would be beneficial for examining other amino acid residues in the AMX binding site of 
IL-1α. In vivo study could help to determine whether or not AMX can inhibit non-
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Technologies that involve recombinant DNA producing recombinant proteins 
have drastically changed the world’s pharmaceutical market. Protein drug research 
development has allowed for the potential treatment of other ailments such as auto-
immune diseases, cancer, hypertension, mental disorders, metabolic diseases, as well as 
cardiovascular disease. Many therapeutic proteins have been successfully produced by 
recombinant DNA technology. The overproduction and purification of recombinant 
proteins is a multibillion-dollar business.  Significant advantages of recombinant protein 
drug therapy make the production efforts not only worthwhile, but also extremely 
important. When recombinant protein expressed as inclusion bodies in E. coli cells, 
multiple steps require to obtain soluble and biologically active target protein. As multiple 
steps leading to lower yield of pure protein that could hindered the study of many 
proteins and driven up the cost of many pharmaceuticals. Therefore, there is great interest 
to pharmaceutical and biotechnology industries to develop an efficient strategy for 
purification of recombinant proteins. In this context, several affinity tags have been 
successfully proposed for the purification of recombinant proteins.  However, the 
currently commercially available affinity tags have some difficulties for example 
requirement of exhaustive purification conditions, high costs of the solutes used for 
fraction elution, protein tags are prone to denature at high conditions, weak solubility 
enhancer, target proteins are not recovered as a fully bioactive form, and limited 
pharmaceutical/biotechnology applications. This study pertains to the successful 
development of a novel solubility affinity tag which can be used for the simple, versatile, 
and cost-effective purification and detection of recombinant proteins expressed as 
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inclusion bodies. In addition, the affinity tag has wide range applications in 
pharmaceutical and biotechnological field. The novel Ark-RUBY-tag facilitates rapid, 
reproducible and single-step purification of recombinant proteins expressed as inclusion 
bodies in E. coli cells as it is shown in purifying IL-1 alpha and D2 domain. Purification 
of ArK-RUBY-fused recombinant protein(s) can be obtained by using imidazole 
fractions. Target protein can be easily removed from the Rd-tag by enzymatic cleavage. 
No requirement for desalting step in order to get purified, target protein. Rd-fused 
recombinant proteins can be quantitatively detected using polyclonal antibodies. Rd-tag 
can be used to purify small peptides. By using Ark-RUBY-tag, purified recombinant 
protein regains fully biologically active form. Therefore, bioactive protein has wide range 
of application in drug-delivery. 
The non-classical secretion of signal peptide-less proteins is still unclear and 
under research. While some proteins have displayed good binding affinities to S100A13, 
the protein involves in non-classical secretion, some critical steps are still ambiguous. For 
example, the mechanism of multi protein complex formation that involves in interleukin-
1 alpha is still unwell understood. Also, there is no suitable answer for how copper 
chelator prevents IL-1 alpha secretion. In this study, in order to understand plausible 
mechanism underlying the role of copper in non-classical secretion of IL-1 alpha, an 
investigation was made to study the effects of copper and different metals on IL-1 alpha. 
Copper involves in many crucial biological reactions in the cells. Even though copper ion 
is toxic when it is free, the mechanism(s) underlies intracellular copper transportation is 
still unknown. It is known that copper involves in non-classical secretion of many signal 
peptide-less proteins. The IL-1α is shown to bind to Cu++ with apparent binding constant 
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value in nanomolar range. It seems that Cu++ induces protein conformational changes 
leading to protein dimerization which we believe the dimerization event play a crucial 
role in protein secretion by non-conventional mechanism. Also, we believe that S100A13 
is Cu++ donor since S100A13 is copper binding protein. In this study IL-1α was also 
tested to interact with several metals in order to examine whether or not copper is specific 
for dimerization. The results are shown that cupric form of copper is the only metals that 
underlies protein dimerization, whereas cuprous form copper shows good binding with no 
conformational changes. Copper induced IL-1α dimerization was inhibited when 
reducing agents is added, so that an attempt is made to design mutation on Cys134 
position since IL-1α has only one cysteine. The results of this study reveal that the 
dimerization is mediated by disulfide bridge of two cystine. Both monomer and dimer 
form show good binding affinity to S100A13 which suggests that S100A13 binding site 
to IL-1α has no conformational changes.  
In previous study on FGF-1, Amelexanox (AMX), the drug that is used for 
reducing inflammatory reaction, was able to inhibit FGF-1 secretion. The results of this 
study showed that AMX binds to IL-1α in constant affinity in the micromolar range. 
AMX induces protein conformational changes around Cys134 because it prevents protein 
dimerization. Also, AMX shows a good binding to copper which we believe that AMX 
works as copper chelator reagent or it binds to Cys134 and prevents copper to reduce 
Cys134. Another event may occur in dimerization prevention mechanism which is AMX 
converts corpus to cupric which in return it prevents dimerization. The results of AMX 
are promising to design a drug that may help in inhibiting IL-1α secretion that is 
associated with many diseases.                 
